CagriSema Clinical Protocol

Pre-approval, investigational protocol. CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination; Novo Nordisk) is NOT FDA-approved as of 2026-05-13. The REDEFINE Phase 3 program has read out (REDEFINE-1 + REDEFINE-2 simultaneous NEJM publication June 2025); Novo Nordisk submitted the regulatory dossier; FDA review ongoing; PDUFA action date per Novo Nordisk public disclosures. Anticipated FDA submission/action timing is conditional on Phase 3 results and FDA action. This protocol prepares clinicians for CagriSema’s anticipated availability based on REDEFINE Phase 3 readout data; current prescribing requires either (a) off-label co-administration of separate cagrilintide + semaglutide (with cagrilintide itself pre-FDA-approval, this pathway is operationally constrained — see §1.4 and §10) or (b) enrollment in active REDEFINE trials.

1. Purpose, scope, and structural framing

This protocol prepares clinicians for CagriSema’s anticipated availability based on REDEFINE Phase 3 readout data. The combination is a fixed-ratio combination product (cagrilintide 2.4 mg + semaglutide 2.4 mg co-formulated in a Novo Nordisk pen platform), not a clinician-titrated co-administration regimen of separate components. CagriSema is NOT FDA-approved as of 2026-05-13; current clinical use is investigational. The protocol’s twelve sections track the canonical 12-section Module 5 Protocol Template (/Methodology/Protocol Template.md) and the canonical CagriSema research document (/Peptides/CagriSema.md v1.0-final, 2026-05-12).

Cross-canonical wikilinks to [[Cagrilintide Protocol]] (Wave 2 sibling — amylin-component standalone) and [[Semaglutide Protocol]] (GLP-1-component standalone; FDA-approved) anchor component-level depth. The combo-product framing distinguishes CagriSema from clinical co-administration of separate cagrilintide + semaglutide (which would have different pharmacokinetic, tolerability, and regulatory implications — see §1.4 and §9.2).

Table of contents

1. Indication scope and patient phenotypes
2. Selection criteria (inclusion / relative exclusion / contraindications)
3. Pre-treatment workup
4. Initiation protocol
5. Maintenance protocol
6. Side-effect management
7. Plateau and non-response algorithm
8. Discontinuation and tapering
9. Combination rules
10. Patient counseling beats (Pattern Z calibration-anchor-compliant)
11. Source citations
12. Clinical decision tree

Appendices

• A. Verification gate — four-step cycle
• B. Pattern discipline summary
• C. Self-audit and byte-count

---

1. Indication scope and patient phenotypes

1.1 Purpose

Define where CagriSema will apply once available — the indication scope as supported by REDEFINE Phase 3 evidence — and which patient phenotypes within that scope are the protocol’s primary, secondary, and tertiary targets. Per Pattern R.1 / R.2 framing discipline, Section 1 leads with what CagriSema does and for whom, with regulatory exclusions and contraindications carried in §2.

CagriSema is investigational; REDEFINE Phase 3 readout pending FDA action; anticipated FDA submission 2026 conditional on Phase 3 results and FDA review. This protocol is forward-looking — designed to be operationally ready at the moment CagriSema transitions from investigational to FDA-approved.

1.2 What CagriSema is — the combo-product structural framing

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg + semaglutide 2.4 mg, co-formulated for single once-weekly subcutaneous injection in a Novo Nordisk pen platform (the same pen-platform family as Wegovy/Ozempic). The compositional rationale places each component at its maximum-evidence-base dose:

• Cagrilintide 2.4 mg is the plateau region of the Phase 2 cagrilintide monotherapy dose-response curve (Lau DCW et al 2021 Lancet PMID 34798060; cagrilintide 0.3–4.5 mg weekly × 26 weeks; n=706; the 2.4 mg dose produced approximately 9.7% body weight loss at 26 weeks vs placebo approximately 3.0%).
• Semaglutide 2.4 mg is the Wegovy chronic weight management dose per the STEP program (Wilding JPH et al 2021 NEJM STEP 1 PMID 33567185).

Both components are long-acting acylated peptides with C18 fatty diacid acylation supporting matched ~7-day elimination half-lives (Andreasen CR et al 2020 Diabetes Obes Metab PMID 32852869 cagrilintide PK; semaglutide PK per [[Semaglutide]] canonical). Matched half-lives enable synchronous once-weekly dosing with a single 16-week synchronous titration schedule (§4).

1.3 Combo-product vs co-administration regimen — structural distinction

The combo-product structural framing is load-bearing for this protocol. Two structurally distinct scenarios deliver “cagrilintide + semaglutide” to a patient, but they are not pharmacologically, regulatorily, or operationally equivalent:

(A) CagriSema — fixed-ratio combination product (single drug product). A single Novo Nordisk pre-filled pen delivers both components at the appropriate ratio at each titration step. The two components share excipient buffer system, pH stability range, preservative system, and cold-chain handling. The fixed-ratio nature means each dose contains 2.4 mg cagrilintide + 2.4 mg semaglutide (at maintenance) with no clinician latitude to adjust the components independently. The regulatory pathway is a single NDA for the combination product; FDA approval, if granted, will be for the combination as a single regulated drug product.

(B) Co-administration regimen — clinician-titrated separate sema + cagri. Two separate injections (or potentially compounded preparations) administered concurrently, with each component dose adjustable independently. The components are pharmacologically the same molecules as in CagriSema, but the patient receives two separate injectables (separate pens, separate vials, separate excipient systems). Regulatory pathway is the sum of two component regulatory states: semaglutide-component (FDA-approved standalone as Wegovy/Ozempic/Rybelsus); cagrilintide-component (pre-FDA-approval as a standalone compound — no standalone NDA disclosed). The co-administration approach is currently the only way to deliver “amylin + GLP-1” combination pharmacology outside a REDEFINE trial enrollment, but it relies on cagrilintide being available through pre-approval pathways (investigational supply; research-chemical pathway; expanded-access protocols where applicable) — which is operationally constrained for most outpatient clinical practice as of 2026-05-13.

Pharmacologic implications. The Phase 1b human PK study (Enebo et al 2021 Lancet PMID 33894838; NCT03600480; n=95; 20 weeks) characterized co-administered cagrilintide + semaglutide and supported PK consistency with each component’s individual profile — no clinically meaningful PK interaction at the doses studied (albumin has substantial reserve binding capacity at the doses involved). The Phase 3 REDEFINE program (Garvey 2025; Davies 2025) studied the co-formulated combo product, not co-administration. Whether co-administration of separate components produces effect-size identical to the co-formulated combo at the same nominal doses is not formally established in Phase 3; the operational expectation is that delivered peptide doses behave per their molecular pharmacology regardless of formulation, but the trial-population evidence base is for the fixed-ratio combo product.

Tolerability implications. Co-administration of separate components allows clinician latitude to titrate each component independently — useful if one component is producing disproportionate AE burden. The fixed-ratio combo product does not allow this; dose-modification is at the combo-pen level (a step-down in the combo step-down ladder; §4.3) and reduces both components together. For patients where the cagrilintide-component is the AE-driving component, co-administration could in principle permit cagrilintide-component dose reduction while preserving semaglutide-component dose — but this is a clinician-judgment off-label-investigational pattern, not a Phase-3-validated strategy.

Regulatory implications. CagriSema as a combination product receives FDA review as a single drug application; the labeling, indication scope, and post-marketing surveillance dataset are combo-product-specific. Co-administration is by definition outside any combo-product label; each component is used under its own (or its own pre-approval) regulatory state. Pattern AA precision: do not conflate the regulatory state of a combo product with the regulatory states of co-administered components.

1.4 Current prescribing pathway pre-approval

Current prescribing of “CagriSema-equivalent therapy” pre-FDA-approval requires one of:

1. Enrollment in active REDEFINE trials. REDEFINE-3 (NCT05669755; obesity + established CVD/CKD; recruiting), REDEFINE-4 (NCT05669781; East Asian sub-population; recruiting; topline presented ObesityWeek 2025), and REDEFINE pediatric (NCT05669742; adolescent obesity; recruiting) are active as of 2026-05-13. REDEFINE-1 (NCT05567796) and REDEFINE-2 (NCT05394519) have read out and are no longer recruiting. Trial enrollment delivers CagriSema combo product under investigational protocol.

2. Off-label co-administration of separate components. Operationally constrained because cagrilintide is itself pre-FDA-approval as a standalone compound (no standalone cagrilintide NDA publicly disclosed). Investigational supply pathways, expanded-access protocols where Novo Nordisk supports them, and research-chemical pathways (distinct from FDA-regulated drug-compounding) are the routes through which cagrilintide-component is available pre-approval. The semaglutide-component is FDA-approved standalone. Compounded CagriSema as a single co-formulated product is operationally improbable (§10.3): cagrilintide is pre-FDA-approval, so the FDA-shortage-declaration pathway under 503A/503B does not apply to cagrilintide; compounding pharmacies cannot legally compound non-FDA-approved drugs except for limited research/clinical-trial purposes.

3. Compounded semaglutide alone. Not CagriSema; the semaglutide-component-only path operates under 503A/503B during semaglutide shortage periods. This is a single-mechanism GLP-1 RA therapy, not a combo amylin + GLP-1 RA therapy. Patient-counseling beat §10.3.

For clinical purposes, this protocol assumes the post-approval state in §3–§10 operational content. §10.3 and §10.6 carry the pre-approval-specific counseling beats.

1.5 Indication categories — REDEFINE-anchored

The REDEFINE Phase 3 program supports two anchored indications and three pending indications.

Indication 1 — Chronic weight management in adults with obesity without T2D (REDEFINE-1-anchored). Pivotal trial: REDEFINE-1 (Garvey WT et al 2025 NEJM PMID 40544433; NCT05567796; n=3,417; 68 weeks; 4-arm placebo-controlled design — CagriSema combo + cagrilintide-alone + semaglutide-alone + placebo). BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Primary endpoint: percent change in body weight from baseline at week 68 (treatment-policy estimand consistent with ICH E9 R1). Effect-size anchor: CagriSema combo arm 22.7% body-weight reduction (adherent estimand) / −20.4 percentage-point treatment-policy treatment difference vs placebo; cagrilintide-alone arm 11.8%; semaglutide-alone arm 16.1%; placebo arm 2.3–3.0%. Approximately 40% of CagriSema-arm participants achieved ≥25% body weight loss. Phenotype primary target: adults with obesity (BMI ≥30) or overweight with weight-related comorbidity (BMI ≥27 with hypertension, dyslipidemia, OSA, ASCVD, or pre-diabetes), without T2D at enrollment. Pattern AA precision: this is the trial-supported indication; FDA approval pending.

Indication 2 — Chronic weight management in adults with obesity + T2D (REDEFINE-2-anchored). Pivotal trial: REDEFINE-2 (Davies MJ et al 2025 NEJM PMID 40544432; NCT05394519; n=1,206; 68 weeks; 2-arm placebo-controlled design with 3:1 randomization — 904 CagriSema : 302 placebo). BMI ≥27 + T2D. Primary endpoint: percent change in body weight from baseline at week 68 (treatment-policy estimand). Effect-size anchor: CagriSema arm −13.7% body-weight reduction; placebo arm −3.4% body-weight reduction; estimated treatment difference −10.4 percentage points favoring CagriSema (95% CI −11.2 to −9.5; P<0.001). Superiority over placebo demonstrated. Secondary glycemic endpoint: HbA1c reduction substantive in CagriSema arm vs placebo; hypoglycemia incidence low (consistent with non-insulin-secretagogue mechanism of both components). Phenotype primary target: adults with obesity + T2D (BMI ≥27 + diagnosed T2D), including patients on metformin or other non-insulin oral antihyperglycemics; insulin-treated patients included with attention to insulin dose adjustment at initiation. Pattern AA precision: this is the trial-supported indication for obesity + T2D; FDA approval pending. Pattern V precision: this is placebo-controlled, NOT active-comparator vs semaglutide 2.4 mg. The effect size to anchor in clinical counseling is −13.7% vs placebo −3.4% (−10.4 pp treatment difference), NOT a sema-vs-CagriSema head-to-head differential.

Indication 3 (pending) — Obesity + established CVD/CKD with cardiovascular outcomes (REDEFINE-3 recruiting). REDEFINE-3 (NCT05669755) is the CagriSema cardiovascular outcomes Phase 3 trial; readout pending. Class-context: SELECT (Lincoff AM et al 2023 NEJM PMID 37952131; n=17,604; semaglutide MACE HR 0.80 in obesity + established CVD without T2D) is the load-bearing CV-outcomes Phase 3 for the semaglutide-component of CagriSema. Whether the cagrilintide-component augments, attenuates, or leaves unchanged the CV-outcomes signal is the empirical question REDEFINE-3 addresses. Pattern AA precision: this is investigational; REDEFINE-3 readout pending; no FDA-approved CV-risk-reduction indication for CagriSema exists.

Indication 4 (pending) — East Asian sub-population (REDEFINE-4 recruiting). REDEFINE-4 (NCT05669781) Phase 3 in East Asian adults with obesity. Topline data presented at ObesityWeek 2025 (November 2025 Atlanta) indicated effect-size profile consistent with REDEFINE-1 in this sub-population; full publication pending.

Indication 5 (pending) — Adolescent obesity (REDEFINE pediatric recruiting). REDEFINE pediatric (NCT05669742) mirrors the [[Semaglutide]] STEP TEENS pediatric program. Readout pending. Pediatric clinical use is research-state-pending.

No CagriSema-specific evidence base (as of 2026-05-13): MASH (the semaglutide-component MASH approval per ESSENCE PMID 40226716 is for semaglutide standalone, not CagriSema combo); kidney outcomes (FLOW PMID 38078870 for semaglutide standalone); HFpEF (STEP-HFpEF for semaglutide standalone); cognitive outcomes (evoke/evoke+ for semaglutide). These indications belong to the semaglutide-component standalone literature ([[Semaglutide Protocol]]) and do not transfer automatically to CagriSema; whether the combo product produces effects in these conditions beyond the semaglutide-component standalone is empirically uncharacterized.

1.6 Phenotype-targeting taxonomy

Within the REDEFINE-anchored indication scope (Indications 1–2 above), CagriSema’s phenotype targeting refines patient selection. The Module 5 phenotype taxonomy dimensions (§1.3 in Protocol Template) apply as follows:

Metabolic phenotype. Insulin-resistant obesity is the dominant REDEFINE-2 enrollment phenotype (BMI ≥27 + T2D); insulin-sensitive obesity is part of REDEFINE-1 enrollment (BMI ≥30 or ≥27 with non-diabetic comorbidity). CagriSema’s amylin-component contribution may have additional relevance for postprandial glycemia and meal-size phenotype (slowed gastric emptying via hindbrain area postrema satiety per Lutz 2010 PMID 18025463 and Larsen et al 2023 Cell Metab PMID 36584289). Pattern V precision: postprandial glycemia effect direction in non-T2D CagriSema patients is research-state-incomplete at the mechanism-anchored level; population-level glycemic outcomes in REDEFINE-2 (T2D population) are characterized.

Adiposity distribution. Visceral-dominant and subcutaneous-dominant adiposity were both represented in REDEFINE enrollment; sub-population effect-size by adiposity distribution per Garvey 2025 + REDEFINE-1 post-hoc analyses (ObesityWeek 2025). The 22.7% mean body-weight reduction in REDEFINE-1 includes patients across the adiposity distribution spectrum.

Appetite phenotype. Two-component mechanism integration produces effect across hyperphagia-dominant, slow-satiety-dominant, and hedonic-eating-dominant appetite phenotypes. The cagrilintide-component primarily addresses hindbrain-mediated satiety and meal-size reduction; the semaglutide-component primarily addresses hypothalamic and mesolimbic appetite suppression. The two-pathway design is mechanistically suited to patients with mixed appetite phenotype where single-mechanism therapy may produce incomplete satiety effect. Pattern V precision: appetite-phenotype-stratified effect-size differentials within REDEFINE program are research-direction; population-level effect-size in REDEFINE-1 and -2 is the load-bearing evidence.

Energy-expenditure phenotype. CagriSema effect on resting energy expenditure (REE) and adaptive thermogenesis is not characterized at primary-endpoint level in REDEFINE program; class-context from semaglutide and tirzepatide literature suggests pharmacologic weight loss does not protect against adaptive-thermogenesis-mediated counter-regulation. Patients with prior adaptive-thermogenesis-prone weight-regain history are within CagriSema’s target population but should be counseled on long-term-maintenance framing (§7.3 set-point reset framing; §8.5 post-discontinuation regain).

Comorbidity load. REDEFINE-1 enrollment included non-diabetic obesity with weight-related comorbidities (hypertension, dyslipidemia, OSA, pre-diabetes); REDEFINE-2 enrollment included obesity + T2D. Polycondition phenotype (T2D + ASCVD + CKD + MASH) was not specifically REDEFINE-enrolled — for polycondition patients, the semaglutide-component standalone evidence base (SELECT for CVD; FLOW for CKD-in-T2D; ESSENCE for MASH F2/F3) is currently the load-bearing evidence; CagriSema combo polycondition effect requires REDEFINE-3 readout and additional indication-specific Phase 3 data for full characterization.

Pharmacologic history. Prior GLP-1 RA exposure (response/non-response/intolerance) is a relevant phenotype dimension. Patients with prior single-mechanism GLP-1 RA exposure (semaglutide or tirzepatide) and either incomplete response or plateau may be candidates for CagriSema once available, via the combo-additive mechanism rationale (§2.4 of canonical; §7 plateau algorithm of this protocol). Pattern V precision: REDEFINE program did not specifically enroll prior-GLP-1-RA-failure phenotype as a separate sub-population; effect-size in this sub-population is extrapolated rather than directly anchored.

Life-stage modifier. Reproductive-age female (pregnancy planning is a discontinuation trigger — §8.4 washout arithmetic); perimenopausal/menopausal; older adult (≥65, lean-mass concern); adolescent (REDEFINE pediatric recruiting; CagriSema is not approved for adolescents and no adolescent indication exists as of 2026-05-13).

1.7 Mechanism — combo-additive, two-component CNS engagement

CagriSema engages two distinct receptor systems concurrently:

• Cagrilintide component → amylin receptor family (AMY1/AMY2/AMY3 — CTR + RAMP1/2/3 heterodimers per Christopoulos et al 1999 Mol Pharmacol PMID 9374472 and Hay et al 2015 Pharmacol Rev PMID 25898253). Concentrated in hindbrain area postrema (AP) and nucleus of solitary tract (NTS), with secondary expression in hypothalamic and reward-circuit neurons and peripheral sites (pancreatic α/β-cells, kidney, bone, BAT). Downstream satiety via vagal afferent integration → NTS → hypothalamic arcuate signaling → reduced meal size, slowed gastric emptying, modulated reward-based eating (Lutz 2010 PMID 18025463; Larsen et al 2023 PMID 36584289).

• Semaglutide component → GLP-1 receptor (class B GPCR; gene GLP1R). Concentrated in pancreatic β-cells (insulin secretion), hypothalamus (appetite suppression), mesolimbic reward circuits, GI tract (gastric emptying), cardiovascular tissues, and broader CNS expression. Standard GLP-1 RA pharmacology per [[Semaglutide]] canonical.

Combo-additive at population scale. REDEFINE-1 4-arm trial provides component-vs-combo direct comparison within a single trial. CagriSema combo treatment effect of −20.4 pp relative to placebo approximates the arithmetic sum of single-mechanism component effects (cagrilintide-alone −9.5 pp + semaglutide-alone −13.8 pp ≈ 23.3 pp; combo observed −20.4 pp is approximately the arithmetic sum). The population-level data are consistent with combo-additive mechanism integration; whether neuron-level receptor-crosstalk at hindbrain NTS/AP co-localization loci produces neuron-scale synergy beyond population-scale additivity is research-state-open. Pattern Z.research-precision: the protocol uses “combo-additive” as the default framing; “synergistic” is reserved for specific receptor-crosstalk research questions where the strict-mechanism-sense of “effect greater than the sum of parts” is at issue. Avoid “experimental combination” or “untested combo” — REDEFINE-1 and REDEFINE-2 are completed Phase 3 trials with substantive evidence base.

1.8 Cross-reference to case construction

CagriSema clinical cases (presented in §4, §5, §6, §7, §8 examples) are constructed against the REDEFINE-anchored phenotype taxonomy in §1.5–§1.6, using case-construction conventions documented in M5.10 Case Study — Patient Questions. Cases anchored to REDEFINE-1 phenotype (obesity without T2D) cite the 22.7% effect-size anchor with appropriate population qualification; cases anchored to REDEFINE-2 phenotype (obesity + T2D) cite the −13.7% vs placebo −3.4% / −10.4 pp anchor with explicit placebo-controlled framing. Pattern V.metric-axis: each effect-size citation carries per-arm values AND treatment-effect (delta) value; Pattern V.estimand-axis: treatment-policy vs adherent (trial-product) estimands distinguished where the difference is load-bearing.

2. Selection criteria (inclusion / relative exclusion / contraindications)

2.1 Purpose

Define who CagriSema (once available) is for, who it is not for, and who it must not be given to. §2 operationalizes the §1 indication scope into actionable clinical screening criteria. Per Pattern R.1, this section opens with inclusion criteria before relative exclusions and contraindications. Per Pattern AA, every contraindication is anchored to its source (FDA boxed warning, FDA labeled contraindication via the semaglutide-component, post-marketing signal, or REDEFINE-program exclusion criterion).

Pre-approval Pattern AA framing. CagriSema labeling does not yet exist (FDA review ongoing). The selection criteria in this section are constructed by integrating: (a) REDEFINE-1 and REDEFINE-2 enrollment criteria, (b) class-wide GLP-1 RA labeling for the semaglutide-component, (c) emerging cagrilintide-component class considerations from Phase 2/3 trial enrollment, and (d) co-administration regimen criteria for pre-approval clinical use. Pattern AA precision: §2 inclusion criteria reflect trial-enrollment phenotype + anticipated label; §2.4 contraindications reflect FDA boxed warnings and class-wide labeled contraindications via the semaglutide-component and the anticipated cagrilintide-component class considerations.

2.2 Inclusion criteria — REDEFINE-enrolled phenotype

Inclusion criteria are stated as the population the REDEFINE Phase 3 program enrolled, with the anticipated label expected to mirror enrollment criteria.

For Indication 1 — chronic weight management without T2D (REDEFINE-1-enrolled phenotype):

• Adult, age ≥18 years (REDEFINE-1 enrollment lower bound)
• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity:
  • Hypertension (treated or untreated, with documented elevated BP at baseline)
  • Dyslipidemia (treated or untreated, with documented elevated LDL-C or low HDL-C or elevated triglycerides)
  • Obstructive sleep apnea (diagnosed by standard polysomnography or home sleep test)
  • Established atherosclerotic cardiovascular disease (prior MI, prior stroke, prior coronary revascularization, prior peripheral arterial revascularization)
  • Pre-diabetes (HbA1c 5.7–6.4 or fasting glucose 100–125 by ADA criteria)
• No T2D at enrollment (T2D patients route to Indication 2 / REDEFINE-2-anchored selection)
• Adjunct to a reduced-calorie diet and increased physical activity (REDEFINE-1 protocol included structured lifestyle-modification co-intervention; the anticipated label is expected to mirror this — chronic weight management as adjunct to lifestyle modification, not as monotherapy)
• Pregnancy / lactation status: not currently pregnant, not breastfeeding, on contraception if reproductive-age (§8 discontinuation arithmetic applies for pre-conception planning)

For Indication 2 — chronic weight management with T2D (REDEFINE-2-enrolled phenotype):

• Adult, age ≥18 years
• BMI ≥27 (REDEFINE-2 enrollment lower bound for BMI; the REDEFINE-2 population is BMI ≥27 + T2D, distinct from REDEFINE-1’s BMI ≥30 or ≥27 with non-diabetic comorbidity)
• T2D diagnosis per ADA criteria, with HbA1c at enrollment within the REDEFINE-2 enrollment range (per Davies 2025 paper; typically 7.0–10.0% range for Phase 3 T2D weight-management trials)
• On standard background T2D therapy (metformin-treated or metformin-intolerant; with or without SGLT2 inhibitor or DPP-4 inhibitor or sulfonylurea; insulin-treated patients included with attention to insulin dose adjustment at initiation per §6.7)
• Adjunct to reduced-calorie diet and increased physical activity
• Pregnancy / lactation status as Indication 1

Cross-indication inclusion considerations:

• Prior GLP-1 RA exposure (semaglutide, tirzepatide, liraglutide, dulaglutide) is not an exclusion criterion for CagriSema. Patients with prior single-mechanism GLP-1 RA exposure and either tolerability success but incomplete weight-loss response, or plateau at maintenance dose, may be candidates for CagriSema. REDEFINE-1 did not specifically stratify enrollment by prior-GLP-1-RA-experience phenotype (the trial was conducted at a stage in the market where many enrolled patients were GLP-1 RA-naive); REDEFINE-2 enrollment did include some prior-GLP-1-RA-experience patients given the trial duration overlapped with semaglutide/tirzepatide commercial availability. Switching considerations per §8.8 of canonical / §9.5 of this protocol.

• Prior bariatric surgery is not an explicit exclusion criterion; REDEFINE program enrollment included some post-bariatric patients with weight regain. Clinician judgment for post-bariatric anatomy and ongoing surgical follow-up.

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where CagriSema is not contraindicated but where benefit is uncertain, risk is elevated, or trial data are sparse.

Severe gastroparesis or gastroparesis-predisposing comorbidity. Both components delay gastric emptying via mechanism integration (cagrilintide-component via amylin-receptor vagal afferent integration; semaglutide-component via direct GLP-1R GI motility effect). In established severe gastroparesis, the combo additive gastric-emptying delay may worsen anatomical and symptomatic gastroparesis. REDEFINE program excluded severe gastroparesis at enrollment. Relative exclusion; clinician judgment with gastroenterology co-management for milder gastroparesis.

Active or recent (within 12 months) acute pancreatitis. Class-level pancreatitis signal in GLP-1 RA pharmacovigilance per Wen Q et al 2025 Endocrinol Diabetes Metab (PMID 40988099) pooled meta-analysis. The cagrilintide-component pancreatitis class-level status is under-characterized (pramlintide ~20-year post-marketing experience has not surfaced a major pancreatitis signal, but pramlintide is a different molecule with different exposure pattern). REDEFINE program included pancreatitis adjudication; population-scale pancreatitis incidence within trial follow-up windows is low. Severe prior pancreatitis history is a §2.4 contraindication; recent acute pancreatitis (within 12 months) is a relative exclusion with clinician-judgment posture.

Severe gastrointestinal disease. Active IBD flare, severe GERD with esophagitis, severe functional dyspepsia. Both components contribute to GI AE profile; pre-existing severe GI disease may be exacerbated.

Diabetic retinopathy with recent rapid HbA1c improvement risk. Class-level consideration for GLP-1 RA in T2D populations with pre-existing retinopathy. SUSTAIN-6 documented a retinopathy-complication signal in semaglutide patients with rapid glycemic improvement. CagriSema’s semaglutide-component carries this class consideration; the substantive HbA1c reduction in REDEFINE-2 places CagriSema in the rapid-glycemic-improvement risk profile for T2D patients with pre-existing retinopathy. Ophthalmology pre-screening for advanced background DR or proliferative DR with HbA1c ≥9.0 is a relative exclusion / pre-treatment workup trigger (§3.3, §3.6).

Severe renal impairment (eGFR <15). Outside REDEFINE program enrollment range. Clinician judgment with nephrology co-management. Class-level peptide pharmacology of both components is renally tolerant at typical eGFR ranges; severe renal impairment is more about co-administered medication management and AKI risk during severe GI AE (volume depletion).

Severe hepatic impairment (Child-Pugh C). Outside REDEFINE program enrollment. Clinician judgment.

Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging). The appetite-suppression mechanism of both components is contraindicated in disordered eating. ARFID and BED-without-purging are clinician-judgment phenotypes routed to behavioral-health co-management. The combo-additive satiety effect may be more pronounced than single-mechanism therapy and should be considered in the eating-disorder risk-benefit assessment.

Active malignancy on therapy (other than MTC/MEN-2 contraindication — see 2.4). Clinician judgment with oncology co-management. REDEFINE program excluded active cancer at enrollment.

Type 1 diabetes mellitus. REDEFINE program enrolled T2D (REDEFINE-2) but not T1D. Cagrilintide-component class is adjacent to pramlintide (Symlin; FDA-approved for T1D and T2D as insulin adjunct), but CagriSema is investigational in obesity ± T2D, not T1D. Off-trial T1D use is investigational and clinician-judgment only.

Significant prior thyroid nodular disease (without MTC family history; nodules under active surveillance). Class-level GLP-1 RA boxed warning for MTC family/personal history is absolute (§2.4); non-MTC thyroid nodules are clinician-judgment, with attention to baseline thyroid imaging and surveillance pattern.

2.4 Hard contraindications — boxed warnings and labeled contraindications

Hard contraindications are absolute — CagriSema (or the co-administered components pre-approval) must not be initiated, and if discovered during therapy, the molecule is discontinued.

Personal or family history of medullary thyroid carcinoma (MTC). Class-wide FDA boxed warning for GLP-1 RAs based on rodent C-cell tumorigenicity signal (Bjerre Knudsen et al 2010 Endocrinology PMID 20203154). The semaglutide-component of CagriSema inherits this class-wide boxed warning. The cagrilintide-component carries a mechanism-specific consideration via the amylin receptor heterodimer architecture (calcitonin receptor + RAMP — calcitonin is produced by thyroid C-cells; whether cagrilintide-mediated CTR engagement as part of the AMY-receptor heterodimer alters C-cell biology in clinically meaningful ways is research-state-incomplete). Pramlintide adjacent-class precedent: pramlintide (Symlin; FDA-approved 2005; ~20-year post-marketing experience) is a non-acylated short-acting amylin analog engaging the same CTR-RAMP heterodimer architecture; pramlintide labeling does NOT carry MTC contraindication and post-marketing has not surfaced a major MTC signal. The CagriSema combo product is expected to carry the GLP-1 RA class MTC contraindication via the semaglutide-component; whether the cagrilintide-component independently warrants MTC contraindication is a regulatory question pending FDA action on CagriSema NDA. Pattern AA precision: absolute contraindication via class-wide boxed warning attributable to the semaglutide-component; cagrilintide-component independent contribution research-state-incomplete.

Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same boxed-warning source. Absolute contraindication.

Severe prior pancreatitis history (severe acute or chronic). Labeled contraindication or strong-precaution depending on each component’s specific labeling. Anticipated CagriSema labeling will reflect this class consideration. Severe prior pancreatitis is an absolute contraindication for initiation; clinician judgment for milder prior pancreatitis history (>12 months since event; uncomplicated course; alternative etiology excluded).

Known serious hypersensitivity to cagrilintide, semaglutide, or any excipient. Labeled contraindication for the semaglutide-component standalone; anticipated CagriSema labeling will reflect this for both components and the combo formulation.

Pregnancy. Labeled contraindication for the semaglutide-component CWM indication (Wegovy). Anticipated CagriSema labeling will follow this class pattern. Pregnancy is a §8 discontinuation trigger — a patient on CagriSema who becomes pregnant transitions out of protocol immediately with ~35-day washout per §6.8 of canonical and §8.4 of this protocol (synchronous ~7-day half-lives × 5 = ~35 days for both components).

Lactation. Anticipated labeled contraindication / not-recommended status per class-level convention. Lactation-exposure data for both components is research-state-incomplete.

2.5 Worked example — CagriSema selection criteria

Patient A — REDEFINE-1-anchored inclusion. A 47-year-old female, BMI 34, no T2D, hypertension on lisinopril, dyslipidemia on atorvastatin, no MTC/MEN-2 family history, no pancreatitis history, no gastroparesis, not pregnant, on combined oral contraception, no prior GLP-1 RA exposure. Inclusion confirmed for Indication 1 (REDEFINE-1-anchored CWM): BMI ≥30 OR BMI ≥27 with hypertension and dyslipidemia comorbidities; adult; no T2D; on lifestyle modification; no contraindications. Effect-size framing for counseling (§10): 22.7% mean body-weight reduction at week 68 with placebo arm 2.3–3.0% (REDEFINE-1 CagriSema arm); approximately 40% of CagriSema-arm participants achieved ≥25% body weight loss; Pattern V precision: this is the trial-population effect-size for the REDEFINE-1 enrollment phenotype, which Patient A matches.

Patient B — REDEFINE-2-anchored inclusion. A 55-year-old male, BMI 31, T2D on metformin 1000 mg BID + empagliflozin 10 mg daily, HbA1c 8.1, no MTC/MEN-2 family history, no pancreatitis history, mild diabetic retinopathy on most recent dilated exam (12 months ago), no gastroparesis. Inclusion confirmed for Indication 2 (REDEFINE-2-anchored CWM with T2D): BMI ≥27 + T2D; adult; on standard background T2D therapy; no contraindications. Relative considerations: mild DR with HbA1c 8.1 — pre-treatment dilated exam refresh (§3.6) before initiation given anticipated substantial glycemic improvement on CagriSema; counseling beat (§10) includes retinopathy-monitoring beat. Effect-size framing for counseling: CagriSema arm −13.7% body-weight reduction vs placebo −3.4%; treatment difference −10.4 pp favoring CagriSema (95% CI −11.2 to −9.5; P<0.001) at week 68. Pattern V precision: REDEFINE-2 is placebo-controlled, 3:1 randomization (n=904 CagriSema : n=302 placebo), NOT active-comparator vs semaglutide 2.4 mg. Do NOT frame this in counseling as “CagriSema −13.7% vs semaglutide −10.6%” — that earlier framing was Pattern V drift and was cross-canonical-corrected by Stage 4 module-level audit (orchestrator session 2026-05-13). The correct counseling beat anchors on CagriSema-vs-placebo magnitude and treatment difference.

Patient C — relative exclusion (severe gastroparesis). A 52-year-old female, BMI 35, T2D, established severe gastroparesis on metoclopramide and dietary modification with gastric-emptying scintigraphy showing markedly delayed emptying. Relative exclusion — anticipated combo-additive gastric-emptying delay would likely worsen gastroparesis. Clinician judgment with gastroenterology co-management; alternative pharmacotherapy (SGLT2 inhibitor for T2D; surgical bariatric consultation; non-GLP-1 weight-management approach) is the preferred path.

Patient D — hard contraindication (MTC family history). A 38-year-old male, BMI 36, no T2D, paternal family history of MTC diagnosed at age 42 with subsequent total thyroidectomy. Absolute contraindication — class-wide GLP-1 RA boxed warning for MTC family history. Out of protocol. Alternative non-GLP-1 weight-management pathway (behavioral / surgical bariatric / non-GLP-1 pharmacotherapy).

Patient E — pre-approval co-administration consideration. A 49-year-old female, BMI 32, no T2D, hypertension and dyslipidemia, prior semaglutide 2.4 mg with documented weight-loss plateau at 11% reduction × 6 months on stable dose, no contraindications. Patient asks about CagriSema. Counseling beat: CagriSema is NOT FDA-approved as of 2026-05-13; REDEFINE Phase 3 readout is complete and NDA is filed; anticipated approval timing per FDA action. Current pathway options: (a) continue current semaglutide with intensified behavioral co-intervention (§7 plateau algorithm); (b) transition to tirzepatide (FDA-approved; SURMOUNT-5 head-to-head shows tirzepatide approximately 6.5 pp more weight loss than semaglutide 2.4 mg at max-tolerated doses); (c) consider REDEFINE trial enrollment if eligible and accessible (REDEFINE-3 is recruiting in obesity + established CVD/CKD, which Patient E does not meet; REDEFINE-1 and -2 have read out and are no longer recruiting); (d) wait for CagriSema FDA approval if patient’s clinical context allows the delay. Pattern AA precision: do not frame CagriSema as “approval pending” with implied imminent timeline — frame as “REDEFINE Phase 3 readout complete; FDA review ongoing; PDUFA action date per Novo Nordisk public disclosures and FDA timeline.” Pattern Z anchor 5 (off-label / extrapolation framing) applies: co-administration of separate semaglutide + cagrilintide is investigational, operationally constrained (cagrilintide pre-approval), and is not the same as future CagriSema combo product.

Pattern AA precision in §2.5. “FDA boxed warning for MTC and MEN-2” is the precise regulatory framing — class-wide for GLP-1 RAs including the semaglutide-component of CagriSema. Anticipated CagriSema labeling for hypersensitivity and pregnancy will follow class convention. “Precaution / cautionary use” framings will be specified at FDA action on CagriSema NDA.

Pattern V cross-check at §2.5. The DR signal from SUSTAIN-6 is a direction-of-effect verification anchor: trial documented complication signal in rapid-HbA1c-improvement sub-population, not in the overall trial population. CagriSema’s substantive glycemic effect in REDEFINE-2 places it in the rapid-glycemic-improvement risk profile for T2D patients; the protocol does not generalize the signal to all CagriSema patients but anchors it to the specific phenotype (advanced background or proliferative DR with rapid glycemic improvement). Pattern V flag, not Pattern AA contraindication.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before CagriSema initiation. §3 is the operational handoff between §2 (selection criteria) and §4 (initiation): a patient who passes §2 screening enters §3 workup; only on workup completion does §4 dose initiation begin.

The CagriSema workup integrates standard Module 5 panel architecture (standard metabolic; diabetes-specific where applicable; organ-baseline panels with class-wide GLP-1 RA considerations; body composition baseline) with combo-product-specific considerations (cagrilintide-component CTR engagement → MTC family-history depth; ophthalmology dilated exam threshold per REDEFINE-2 substantive glycemic effect in T2D patients; the gallbladder surveillance posture appropriate for the high-tier weight-loss effect-size). Pattern W cross-section consistency: every lab listed in §3 reconciles with §5 maintenance monitoring intervals and §6 AE-management triggers.

3.2 Standard metabolic panel — every CagriSema patient

Applies to every patient regardless of indication.

• Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline for class-wide GLP-1 RA considerations (renal hydration-status monitoring during severe GI AE; hepatic baseline for any subsequent MASH-context consideration).
• Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline cardiometabolic profile; longitudinal tracking during weight loss.
• Fasting glucose and HbA1c. For non-T2D CagriSema-1-indication patients, screens for undiagnosed pre-diabetes (would not change indication but is relevant baseline); for T2D CagriSema-2-indication patients, establishes glycemic baseline.
• CBC with differential. Baseline hematologic.
• TSH. Thyroid function baseline. Class-wide consideration via the semaglutide-component MTC-family-history framework (§2.4); also a routine baseline that may surface subclinical thyroid dysfunction relevant to weight phenotype.
• Pregnancy test (β-hCG urine or serum) for reproductive-age patients. §2.4 contraindication and §8.4 pre-conception planning anchor.
• Body weight, height, BMI, waist circumference. Anthropometric baseline; waist circumference for visceral-adiposity tracking.
• Blood pressure (seated, two readings, standardized). Baseline; longitudinal tracking (anticipated BP reduction with substantive weight loss per REDEFINE-1 secondary endpoints).

3.3 Diabetes-specific panel — REDEFINE-2-anchored T2D indication

Applies when CagriSema indication is REDEFINE-2-anchored chronic weight management with T2D.

• HbA1c (above; standard panel). Confirms T2D diagnosis and severity; baseline against which substantive REDEFINE-2 glycemic improvement is tracked.
• Fasting C-peptide. Establishes endogenous insulin reserve. Distinguishes T2D from LADA (latent autoimmune diabetes of adults) where CagriSema-component mechanism response may be attenuated. LADA misclassification as T2D is a Pattern V direction-of-effect risk.
• GAD-65 and IA-2 antibodies if LADA suspected (adult-onset diabetes with normal/low BMI, rapid progression to insulin requirement, atypical clinical course). REDEFINE-2 enrolled T2D, not autoimmune diabetes.
• Diabetes complication screen if not within the last 12 months: dilated retinal exam (§3.6 below — particularly important given anticipated rapid HbA1c improvement on CagriSema); urine albumin-to-creatinine ratio (UACR) for diabetic nephropathy; monofilament / vibratory testing for diabetic neuropathy.
• CGM data review if available. Baseline time-in-range and hypoglycemia frequency for patients on concurrent insulin or sulfonylurea (§6.7 hypoglycemia AE class management). Concurrent-agent dose adjustment is anticipated at CagriSema initiation in insulin- or sulfonylurea-treated patients.

3.4 Pancreas baseline

Applies to every patient regardless of indication; anchors §2.4 contraindication and §6.4 AE-class management.

• Serum lipase, serum amylase. Lipase is more pancreas-specific. Baseline establishes reference for any subsequent AE-driven evaluation.
• Triglycerides (also in §3.2 lipid panel). Hypertriglyceridemic pancreatitis is a distinct etiology relevant to AE differential.
• Pancreatitis-history documentation per §2.4. Patients with severe prior pancreatitis are not initiated.

3.5 Thyroid baseline and MTC family-history depth

Applies to every CagriSema patient. Class-wide consideration via the semaglutide-component boxed warning AND the cagrilintide-component CTR-engagement mechanism question (§2.4).

• TSH (also in §3.2 standard panel).
• Neck examination for thyroid nodules. Documented; any palpable nodule prompts thyroid ultrasound per standard endocrinology practice (not CagriSema-specific but standard pre-treatment for any GLP-1 RA-containing therapy with MTC consideration).
• Family-history depth interview. Specifically documenting any first-degree or second-degree relative with thyroid cancer (any type, with attention to MTC); any MEN-2 syndrome; any history of unexplained early-onset thyroid surgery in the family. If any first-degree MTC or any MEN-2 family history is identified at this step, §2.4 absolute contraindication applies and CagriSema is not initiated.
• Routine calcitonin screening is not generally recommended — the boxed warning is based on rodent C-cell signal; human MTC signal is debated; routine calcitonin screening has high false-positive rate. Clinician-judgment for calcitonin if MTC family history is identified but does not rise to absolute contraindication (e.g., remote second-degree relative with thyroid cancer of uncharacterized type).

3.6 Ophthalmology baseline — semaglutide-component NAION + diabetic retinopathy

CagriSema inherits the semaglutide-component class-differentiated NAION pharmacovigilance signal per Lakhani et al 2025 Am J Ophthalmol (PMID 40383360); the EMA semaglutide labeling reflects this class-differentiation as of June 2025. The cagrilintide-component effect on NAION signal is research-state-incomplete. CagriSema also carries diabetic retinopathy class-consideration via the semaglutide-component for T2D patients with substantive HbA1c improvement.

Pre-treatment ophthalmology workup:

• For non-T2D CagriSema-1-indication patients: dilated retinal exam if any of: prior NAION history; first-degree NAION family history; known disc-at-risk anatomy (small or “crowded” optic disc); unexplained visual symptoms. Routine dilated exam pre-initiation in non-T2D patients without these features is not recommended (post-marketing signal is rare-event; routine pre-treatment exam in unselected non-T2D patients has low yield).
• For T2D CagriSema-2-indication patients: dilated retinal exam pre-initiation. HbA1c ≥9.0 or any known background DR triggers expedited (within 4 weeks pre-initiation) dilated exam. The substantive REDEFINE-2 glycemic effect places this population in the rapid-glycemic-improvement risk profile. Patients with proliferative DR or advanced background DR are routed to ophthalmology pre-clearance before CagriSema initiation. Pattern V precision: this is the specific phenotype where the rapid-glycemic-improvement DR signal applies; non-DR or mild-DR T2D patients are not in this risk profile but the dilated exam is still pre-treatment standard for any T2D-indication GLP-1 RA initiation.

3.7 Body composition baseline

• Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA preferred for accuracy; BIA more accessible. Pre-treatment baseline against which §5 maintenance monitoring tracks lean-mass preservation vs total-weight change. CagriSema’s high-tier weight-loss effect-size (REDEFINE-1 22.7%; REDEFINE-2 −13.7%) makes body-composition tracking clinically meaningful — lean-mass loss during pharmacologic weight loss is a documented class concern across GLP-1 RA-containing therapies.
• Hand-grip strength or sit-to-stand timed test. Functional strength baseline; particularly relevant for ≥65 age phenotype where sarcopenia risk during weight loss is a clinical concern.

3.8 Gallbladder pre-treatment screen

CagriSema’s high-magnitude weight-loss tier places gallbladder events in the AE management focus (§6.5). Pre-treatment screen:

• Symptom history. Any prior biliary colic episode, prior cholelithiasis on imaging, prior cholecystectomy.
• No routine pre-treatment biliary imaging in asymptomatic patients. Class-level convention.

3.9 MASH / hepatic baseline

Applies if baseline phenotype suggests MASH risk (obesity + elevated AST/ALT in §3.2 panel; T2D + elevated waist circumference; documented metabolic dysfunction with hepatic enzyme elevation). CagriSema is NOT FDA-approved for MASH; the semaglutide-component standalone has the MASH F2/F3 indication per ESSENCE (Sanyal AJ et al 2025 NEJM PMID 40226716), and that indication does not transfer to CagriSema combo.

For CagriSema candidates with MASH risk profile:

• FIB-4 score calculated from age × AST / [platelets × √ALT]. Low <1.3; indeterminate 1.3–2.67; high >2.67.
• Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Stratification: low <8 kPa, indeterminate 8–12 kPa, high >12 kPa for advanced fibrosis.
• Hepatology co-management for confirmed MASH F2/F3 — and counseling beat (§10) clarifying that CagriSema is NOT FDA-approved for MASH; for the patient with MASH F2/F3 indication, semaglutide standalone (Wegovy, per ESSENCE) is the FDA-approved option.

3.10 Cardiovascular baseline — REDEFINE-3-anchored CV-risk profile

CagriSema CV risk-reduction indication is pending REDEFINE-3 readout; CV risk-reduction is NOT a currently-supported indication. For patients with established CVD considering CagriSema for the chronic weight management indication, baseline CV workup is appropriate:

• ECG (12-lead). Baseline rhythm, conduction status, QT considerations.
• High-sensitivity troponin if symptomatic baseline. Rule out unstable ASCVD; ACS within 60 days is a relative exclusion pending CV stabilization.
• Echocardiogram if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60). Note: CagriSema HFpEF investigational-extension is not in the public pipeline; the semaglutide-component standalone HFpEF data (STEP-HFpEF, STEP-HFpEF-DM) does not transfer automatically to CagriSema combo.

3.11 Worked example — CagriSema pre-treatment workup

For Patient A (REDEFINE-1-anchored CWM without T2D, BMI 34, hypertension, dyslipidemia): standard metabolic panel (§3.2), pancreas baseline (§3.4), thyroid + family-history depth (§3.5), body-composition BIA or DEXA (§3.7), gallbladder symptom screen (§3.8). Ophthalmology dilated exam not routinely required in non-T2D unless NAION risk features present (§3.6). MASH-risk screen via FIB-4 calculation from standard panel; elastography if FIB-4 indeterminate or high.

For Patient B (REDEFINE-2-anchored CWM with T2D, BMI 31, HbA1c 8.1, mild DR 12 months ago): standard metabolic panel (§3.2), full diabetes-specific panel (§3.3) including HbA1c, fasting C-peptide, UACR, monofilament; dilated retinal exam pre-initiation given HbA1c 8.1 + known DR — refresh dilated exam if older than 6 months (§3.6); pancreas and thyroid baseline (§3.4, §3.5); body-composition baseline (§3.7); gallbladder symptom screen (§3.8); ECG baseline if any CV risk factors (§3.10).

Pattern W cross-check at §3.11. Every lab in the worked-example panels reconciles with §5 monitoring intervals (HbA1c at month 4, 7, 10, 13 in Y1 for T2D patients; UACR annually; body-composition reassessment at 6 months; weight + BP at every visit) and §6 AE-trigger labs (lipase symptom-prompted, not scheduled; thyroid imaging clinical-suspicion only, not routine surveillance).

4. Initiation protocol

4.1 Purpose

Define the starting doses, synchronous titration schedule, and tolerability-management cadence for CagriSema initiation. §4 is the time-sequenced action plan from Day 0 (first dose) through Week 17 (target-dose attainment for the combo product) — the period during which the patient transitions from naive to maintenance-stable.

§4 is where Pattern Z calibration anchors are most operationally relevant. The initiation period is when patient adherence is most fragile, GI tolerability is most challenging (and combo-additive vs single-mechanism), and clinician counseling has the greatest influence on continuation vs discontinuation. Pattern Z anchor 4 (comparator framing) and anchor 5 (off-label / investigational transparency) appear in §10 counseling beats specifically because §4 initiation is the conversational anchor for those Pattern Z applications.

4.2 Starting dose — synchronous low-dose initiation

Both components start at sub-therapeutic doses for tolerability-priming. The REDEFINE protocol initiation dose:

• Cagrilintide-component: 0.3 mg subcutaneous once weekly
• Semaglutide-component: 0.25 mg subcutaneous once weekly

Both components are delivered in the single CagriSema pre-filled pen at the appropriate Week 1–4 titration step ratio. The semaglutide-component 0.25 mg mirrors the Wegovy 2.4 mg titration starting dose; the cagrilintide-component 0.3 mg reflects cagrilintide-specific Phase 2 dose-response with 0.3 mg as the lowest-tolerability-priming dose. Both starting doses are sub-therapeutic for weight-loss effect — the purpose is GI-AE attenuation prior to escalation.

4.3 Synchronous titration schedule

The REDEFINE-1 and REDEFINE-2 titration schedule (synchronous cagrilintide + semaglutide dose escalation):

Week	Cagrilintide dose	Semaglutide dose	Notes
1–4	0.3 mg	0.25 mg	Initiation; both components at starting dose
5–8	0.6 mg	0.5 mg	First escalation
9–12	1.2 mg	1.0 mg	Second escalation
13–16	1.8 mg	1.7 mg	Third escalation
17+	2.4 mg	2.4 mg	Maintenance dose

Total titration period: 16 weeks to target dose, with Week 17 being the first target-dose week. Both components escalate synchronously because matched ~7-day half-lives make synchronous escalation operationally simplest; the combo pen delivers fixed-ratio doses at each titration step.

Slow-titration option. Each interval doubled — Week 1–8: 0.3/0.25 mg; Week 9–16: 0.6/0.5 mg; Week 17–24: 1.2/1.0 mg; Week 25–32: 1.8/1.7 mg; Week 33 onward: 2.4/2.4 mg. Total: 32 weeks to target dose. Used for patients with persistent moderate-severity GI AE at any standard-schedule step. A patient on slow titration is not on a different protocol; they are on the standard protocol with a stretched timeline. Pattern AA precision: the standard schedule is anticipated label-recommended; the slow-titration variant is anticipated clinician-judgment within label-permitted clinical-judgment latitude.

Step-down (de-titration) option. If a patient develops persistent moderate-severity GI AE at any titration step that does not stabilize within 2–4 weeks at hold, step down to the prior titration step for an additional 2–4 weeks before re-attempting escalation. Step-down is bidirectional within the standard ladder; persistent intolerability at the 0.3/0.25 mg starting dose triggers reconsideration of CagriSema as the right molecule for the patient (§7 plateau / non-response algorithm; §8 discontinuation).

4.4 GI tolerability management at each titration step

CagriSema’s combo-additive GI AE profile is the dominant tolerability challenge. The AE profile per REDEFINE-1 4-arm data: GI AEs (nausea, vomiting, diarrhea, constipation) incidence higher in CagriSema arm than either single-mechanism arm — combo-additive contribution to AE burden, not synergistic / disproportionate worsening. Most AEs are mild-to-moderate, transient during the 16-week titration phase, and amenable to titration management.

Anticipatory framing at each step:

• Week 1–4 (0.3/0.25 mg starting dose). Nausea is the most common early AE — typically mild and self-limited within 5–7 days for many patients; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size and meal-composition counseling. The combo-additive contribution may make the starting-step GI AE more pronounced than single-mechanism semaglutide 0.25 mg starting; counsel patient that this is anticipated and attenuates with adaptation.

• Week 5–8 (0.6/0.5 mg first escalation). Re-emergence of nausea at dose increase is anticipated and counseled-for. If moderate-severity persists beyond 2 weeks at this step, hold for an additional 2–4 weeks before escalating to Week 9 step (slow-titration de facto applied at this specific step).

• Week 9–12 (1.2/1.0 mg second escalation). Continued GI AE attenuation expected as steady-state at each prior dose is established (5 half-lives ≈ 5 weeks per component). Some patients enter the appetite-suppression-dominant phase here with reduced meal size and pre-prandial satiety.

• Week 13–16 (1.8/1.7 mg third escalation). Maintenance-tier dose approach. Eructation (“sulfur burps”) emerges as a semaglutide-component-specific AE at higher doses; reassurance and food-pairing adjustments are first-line. Constipation can become the dominant GI pattern at maintenance-tier doses for some patients.

• Week 17+ (2.4/2.4 mg maintenance dose). Target dose attained. Continued attenuation of GI AE expected over subsequent 4–8 weeks at stable dose. Hydration emphasis remains throughout (rare AKI signal during severe GI AE with volume depletion is a class consideration).

Pharmacologic management:

• Nausea — first-line non-pharmacologic. Reduce meal size; slow eating pace; low-fat / non-greasy meal composition; hydration consistency.
• Nausea — first-line pharmacologic. Ondansetron 4 mg PRN; scheduled dosing in the 2–3-day post-injection window for moderate-severity. Cross-reference with QT considerations in concurrent medications.
• Vomiting — assessment. Distinguish protocol-related vomiting (expected, attenuates) from acute-pancreatitis-suspect vomiting (severe abdominal pain, persistent, with lipase elevation — §6.4 algorithm).
• Diarrhea / constipation. Bowel-pattern-specific management; loperamide PRN per standard dosing for diarrhea; osmotic laxative (polyethylene glycol) for constipation.

4.5 Early monitoring cadence

Typical CagriSema initiation cadence: contact at Week 2 (post-first-dose tolerability check), Week 5–6 (after first titration step), Week 9–12 (mid-titration tolerability and adherence), Week 17–20 (target-dose attainment confirmation and §5 maintenance transition).

For T2D patients (REDEFINE-2-anchored), add HbA1c reassessment at Week 12–16 to inform dose-vs-target decision-making for concurrent T2D agents. Substantive glycemic improvement is anticipated during titration; concurrent insulin or sulfonylurea dose may need reduction at multiple titration steps (§6.7).

Contact modality (in-person vs telehealth vs message) is practice-specific. Escalation triggers for in-person evaluation within 48 hours: severe persistent abdominal pain, vomiting blood, acute vision change (NAION-suspect), signs of severe AE, significant unintended weight loss exceeding the protocol’s expected trajectory.

4.6 Worked example — CagriSema initiation

Patient A (REDEFINE-1-anchored CWM without T2D). 47-year-old female, BMI 34, hypertension on lisinopril, dyslipidemia on atorvastatin, GLP-1 RA-naive.

Starting dose: CagriSema 0.3 mg cagrilintide + 0.25 mg semaglutide subcutaneous once weekly. Week 1 telephone or telehealth check-in at Day 3–5 to assess tolerability of first dose. Standard schedule with anticipated escalation to 0.6/0.5 mg at Week 5, 1.2/1.0 mg at Week 9, 1.8/1.7 mg at Week 13, 2.4/2.4 mg at Week 17.

Counseling beat at initiation visit (per §10): “CagriSema combines two mechanisms — cagrilintide acts on amylin receptors in the brainstem to reduce meal size and slow gastric emptying; semaglutide acts on GLP-1 receptors to reduce appetite. The two work together in a way that’s been shown in the REDEFINE-1 trial to produce about 22.7% body weight loss at 68 weeks on average, with about 40% of patients achieving 25% or more. That’s at the high end of what’s been demonstrated in obesity Phase 3 trials. The combination also produces more GI side effects than either single component, which is why we titrate slowly over 16 weeks. The slow titration is part of the protocol; it isn’t optional, and there’s a good reason for it. Most patients tolerate the titration without significant disruption; some patients need the slow-titration option of doubling each interval. We’ll check in at Week 2, Week 5–6, Week 9–12, and Week 17 to assess tolerability and adjust pace if needed.”

Patient B (REDEFINE-2-anchored CWM with T2D). 55-year-old male, BMI 31, T2D on metformin 1000 mg BID + empagliflozin 10 mg daily, HbA1c 8.1, mild background DR confirmed on dilated exam 4 weeks ago.

Starting dose: CagriSema 0.3 mg cagrilintide + 0.25 mg semaglutide subcutaneous once weekly. Concurrent T2D agent management: continue metformin and empagliflozin; sulfonylurea not on regimen so no immediate hypoglycemia dose adjustment; HbA1c 8.1 is above individualized target, so glycemic improvement on CagriSema is the goal direction.

Standard titration schedule. Week 12–16 HbA1c reassessment anticipated; if HbA1c approaching individualized target (typically <7.0 for most adults; individualized per ADA/EASD) with concurrent agents at current doses, no concurrent-agent adjustment needed; if HbA1c trajectory faster than expected with hypoglycemia risk emerging, concurrent-agent step-down may be needed.

Counseling beat at initiation visit: “CagriSema for your situation — obesity plus T2D — was studied in REDEFINE-2, which compared CagriSema to placebo in 1,206 patients with both conditions. The CagriSema group lost about 13.7% of body weight at 68 weeks; the placebo group lost about 3.4%. The difference favoring CagriSema is about 10.4 percentage points, which is statistically significant and clinically substantial. The trial was placebo-controlled, not a head-to-head versus other GLP-1 medications — so we have CagriSema-versus-placebo magnitude as the core comparison. HbA1c also improved substantially in the CagriSema group; for your situation with HbA1c 8.1, we’d expect substantial improvement. Because your HbA1c is elevated and you have mild background DR, we’ll watch closely for retinopathy progression during the period of rapid HbA1c improvement — that’s a class consideration. The GI side-effect profile applies the same way as for non-diabetic patients; slow titration over 16 weeks is the standard protocol.”

Pattern V applied to §4.6. Effect-size anchors at target dose: REDEFINE-1 22.7% in non-T2D obesity; REDEFINE-2 −13.7% vs placebo −3.4% (−10.4 pp) in T2D + obesity. Direction-of-effect for sub-population deviations from REDEFINE enrollment (e.g., BMI 27–30 with non-T2D-non-comorbidity, outside REDEFINE-1 enrollment) is not established — counseling does not generalize specific effect-sizes to non-enrolled phenotypes without explicit population qualification.

Pattern AA applied to §4.6. The titration schedule is anticipated label-recommended (the REDEFINE protocol schedule mirrored standard combo-product titration design); the slow-titration variant is anticipated clinician-judgment within label. CagriSema is investigational pre-approval — the “anticipated label” framing is the protocol’s pre-approval Pattern AA discipline. Once FDA action on the NDA produces labeling, the protocol’s §4 will reconcile against the actual label.

Pattern V.estimand-axis at §4.6. Effect-size estimands matter for combo-product characterization. REDEFINE-1 reports both treatment-policy (consistent with intention-to-treat) and adherent (trial-product) estimands; the 22.7% value cited is the adherent estimand; the −20.4 pp value cited is the treatment-policy treatment difference vs placebo. Counseling typically uses the adherent figure (22.7%) for patient communication and the treatment-policy figure for regulatory/Pattern V discipline. REDEFINE-2 reports treatment-policy estimand consistent with ITT; the −13.7% and −10.4 pp values are treatment-policy.

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the protocol: target dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). §5 is the longest operational phase of CagriSema therapy — for a patient who tolerates target dose and continues therapy, maintenance is open-ended for the duration of clinical benefit.

5.2 Target dose

Target dose: CagriSema 2.4 mg cagrilintide + 2.4 mg semaglutide subcutaneous once weekly (single combo pen). Both components are at maximum-evidence-base monotherapy dose; the combination effect derives from the two non-overlapping satiety pathways operating concurrently, not from higher-than-monotherapy dosing of either component.

Reduced-dose maintenance. For patients who require step-down due to persistent maintenance-dose AE intolerability, reduced-dose maintenance options (1.8/1.7 mg, or 1.2/1.0 mg) are anticipated within clinical-judgment latitude. These are not Phase-3-validated maintenance doses (REDEFINE program studied 2.4/2.4 mg as the maintenance dose); they are clinician-judgment dose-reduction options to preserve some combo benefit when target-dose tolerability is the limiting factor. Pattern AA precision: clinician-judgment within anticipated label, not label-mandated.

5.3 Monitoring intervals

Monitoring intervals for the maintenance phase: 3-month visits during the first year on target dose, 6-month visits thereafter for stable patients. The exact cadence depends on indication and on baseline comorbidity burden.

For REDEFINE-1-anchored CWM without T2D: Months 4, 7, 10, 13 during the first year on 2.4/2.4 mg (approximately quarterly from target-dose attainment); every 6 months thereafter for stable patients. At each visit: weight, BP, brief AE-and-adherence interview, body-composition reassessment (BIA or DEXA quarterly in Y1, biannually thereafter), lipid panel annually, MASH-risk reassessment via FIB-4 calculation from annual hepatic panel if MASH-risk baseline.

For REDEFINE-2-anchored CWM with T2D: HbA1c at Month 4 (interim trajectory check; substantive HbA1c effect anticipated to approach steady-state by Month 6), Month 7, then quarterly during Y1; every 6 months thereafter for stable patients. UACR annually. eGFR quarterly during Y1, biannual thereafter (renal function tracking during substantive glycemic and weight improvement). Lipid panel annually. Body composition tracking per §3.7 baseline.

Class-wide monitoring (every CagriSema patient):

• Weight + BP at every visit
• Lipase if any abdominal-pain symptom report (symptom-prompted, not scheduled)
• Annual TSH (low-yield in stable patients without symptoms; clinician-judgment)
• Ophthalmology dilated exam annually for T2D patients with any baseline DR; clinician-judgment frequency for non-T2D patients without NAION risk features
• Gallbladder symptom inquiry at every visit; biliary imaging if symptomatic

5.4 Dose-adjustment triggers

Dose adjustment in maintenance is driven by three trigger categories:

Target-not-met. Effect is sub-threshold for clinical benefit at current dose. For CWM indications, the typical threshold is <5% body-weight reduction at Month 6 on maintenance dose with documented adherence — triggers transition to §7 non-response algorithm. CagriSema-specific non-response thresholds per FDA labeling at approval (anticipated to mirror class-level conventions).

Target-overshoot. Effect exceeds clinical target. Rare in CWM but unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below 22 in a patient whose initial BMI was 33) triggers dose-down to 1.8/1.7 mg or 1.2/1.0 mg with re-evaluation at Month 3 on reduced dose. For T2D patients with hypoglycemia risk on concurrent insulin or sulfonylurea — protocol typically titrates down the concurrent agent rather than CagriSema (§6.7).

AE-emergent. New or worsening AE that responds to dose reduction. Most common scenario: persistent moderate-severity GI AE at maintenance 2.4/2.4 mg that does not respond to symptomatic management → step-down to 1.8/1.7 mg with Month 3 reassessment (whether reduced dose maintains adequate weight-loss effect for the patient and whether AE attenuates).

5.5 Worked example — CagriSema maintenance

Patient A maintenance (REDEFINE-1-anchored, Month 7 on 2.4/2.4 mg). Weight reduction at Month 7: 11% from baseline (on-trajectory per REDEFINE-1 median curve; the 22.7% figure is mean week-68 endpoint, with weight loss continuing through Month 17 / Week 68). BP improved (SBP −12 mmHg from baseline); lipid panel improved; mild residual nausea at the 2–3-day-post-injection window managed with PRN ondansetron. Body-composition reassessment at Month 6 showed approximately 25% of lost mass as lean mass (within typical pharmacologic-weight-loss range; not yet in the high-lean-mass-loss tier requiring intervention). Plan: continue 2.4/2.4 mg maintenance; next visit Month 10; body-composition reassessment Month 12; consideration of lean-mass-stack addition (§9) if subsequent body-composition tracking shows lean-mass loss exceeding 30% of total loss.

Patient B maintenance (REDEFINE-2-anchored, Month 7 on 2.4/2.4 mg). Weight reduction at Month 7: 7% from baseline (on-trajectory for REDEFINE-2 median curve, anticipating continued reduction through Month 17 / Week 68 endpoint −13.7%). HbA1c reduced from baseline 8.1 to 6.7 at Month 7 — substantive glycemic improvement; below individualized target of 7.0. Concurrent T2D agent decision: empagliflozin continued (CV/kidney-benefit-justified independent of HbA1c); metformin continued (T2D foundation therapy). UACR stable. eGFR stable. Mild background DR reassessment at Month 6 dilated exam showed no progression. Plan: continue 2.4/2.4 mg maintenance; quarterly HbA1c; annual UACR; annual dilated exam.

Patient F (worked example — AE-emergent dose-down). A 62-year-old female on CagriSema 2.4/2.4 mg for non-T2D CWM, Month 5 on maintenance, persistent Grade 2 nausea (recurring 3–4 days after each weekly injection) with associated 2 kg unintended weight loss beyond the patient’s stated weight-loss goal floor in the past 6 weeks. Symptomatic management (scheduled ondansetron + meal-composition counseling) has not stabilized the Grade 2 nausea.

Protocol response. Dose-down to 1.8/1.7 mg with Month 3 reassessment. Anticipated outcome: AE attenuation; some loss of weight-loss-driving effect — re-establishing equilibrium at a higher BMI than 2.4/2.4 mg would produce but at improved patient-experience. Pattern Z calibration anchor: patient-preference-anchored decision; a tolerable but unpleasant Grade 2 profile at 2.4/2.4 mg vs reduced-dose-with-improved-tolerability is the patient’s call within the medically reasonable options. If 1.8/1.7 mg maintains adequate weight-loss effect for the patient at Month 3 reassessment, continue indefinitely; if effect inadequate, reconsider §7 non-response framing vs §8 discontinuation.

Pattern W cross-check at §5.5. Monitoring intervals reconcile with §3 pre-treatment panel (every monitoring lab established as baseline) and §6 AE-management algorithms (every AE-trigger lab in monitoring schedule or symptom-prompted basis). Lipase monitored on symptom-prompted basis (abdominal pain), not on scheduled-interval basis, per the AC2-26-class system-observations precedent on not screening with low-specificity labs absent symptom.

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the AE categories that apply to CagriSema. §6 is the AE-by-AE-class operational reference — what to expect, when to escalate, when to discontinue. Each AE-class sub-block opens with anticipatory framing (Pattern R), then identification, severity grading, first-line management, escalation triggers, discontinuation triggers.

CagriSema’s AE profile inherits the GLP-1 RA class profile via the semaglutide-component and the amylin-class profile via the cagrilintide-component (less developed; pramlintide adjacent-class reference). The combo-additive contribution to AE burden is documented in REDEFINE-1 4-arm design (CagriSema arm AE incidence higher than either single-mechanism arm); the combo-vs-placebo magnitude in REDEFINE-2 (CagriSema arm vs placebo) characterizes the registrational AE signal.

6.2 GI AE class — the dominant AE class

Anticipatory framing. Combo-additive contribution from both mechanisms (cagrilintide-component slowed gastric emptying via amylin-receptor vagal afferent integration + semaglutide-component slowed gastric emptying via direct GLP-1R GI motility effect + both contributing to central appetite suppression). The AE profile is typically peak-at-dose-escalation and attenuates within 2–4 weeks at stable dose. REDEFINE-1 4-arm prevalence (descriptive; full incidence figures per Garvey 2025 supplementary tables): nausea, vomiting, diarrhea, constipation principal AEs; CagriSema arm > semaglutide-alone arm > cagrilintide-alone arm > placebo. Discontinuation due to GI AE in REDEFINE-1 CagriSema arm higher than placebo but within range of single-mechanism GLP-1 RA Phase 3 trials.

Identification. Patient-reported during early-monitoring contacts (§4) and maintenance visits (§5). Standardized severity grading via CTCAE: Grade 1 (mild, intervention not indicated), Grade 2 (moderate, minimal intervention indicated), Grade 3 (severe, hospitalization indicated), Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1–2.

First-line management. Non-pharmacologic: meal-size reduction; slow eating pace; low-fat / non-greasy meal composition; hydration emphasis. Pharmacologic: ondansetron 4 mg PRN for nausea (scheduled in 2–3-day post-injection window for moderate-severity); loperamide PRN per standard dosing for diarrhea; osmotic laxative (polyethylene glycol) for constipation; reassurance and meal-pairing adjustments for eructation.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 severity beyond 4 weeks at stable dose. Vomiting with severe abdominal pain (assess for pancreatitis — §6.4). Significant unintended weight loss exceeding the protocol’s target trajectory or below the patient’s pre-specified target floor.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference (a tolerable but unpleasant Grade 2 profile is a Pattern Z calibration point — the protocol does not override patient preference for discontinuation by framing tolerability as obligation).

6.3 Gallbladder AE class

Anticipatory framing. GLP-1 RA association with cholelithiasis and cholecystitis is well-documented; mechanism is attributed to weight-loss-rate-related bile-supersaturation and to direct effects on gallbladder motility. CagriSema’s high-tier weight-loss effect-size (REDEFINE-1 22.7%; REDEFINE-2 −13.7%) places gallbladder surveillance in the AE-management focus. REDEFINE program gallbladder AE incidence characterized in trial AE reporting at incidence consistent with rapid weight loss.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is the first-line imaging study; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and symptoms compatible with biliary colic: surgical consultation, typical management trajectory is laparoscopic cholecystectomy. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs (fever, leukocytosis, sepsis). Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) requires urgent ERCP or surgical consultation.

Discontinuation triggers. Recurrent symptomatic gallstones post-cholecystectomy with bile-acid-related pattern: clinician judgment for protocol continuation vs alternative-molecule transition. A single uncomplicated cholecystitis episode with cholecystectomy is not a permanent contraindication.

6.4 Pancreatitis AE class

Anticipatory framing. Acute pancreatitis signal in GLP-1 RA pharmacovigilance has been debated since exenatide-era reports. Wen et al 2025 Endocrinol Diabetes Metab (PMID 40988099) pooled GLP-1 RA RCT meta-analysis characterizes the class-level signal with the typical caveats (heterogeneous trial pooling; numerical-vs-significant signal). Pivotal-trial data have not demonstrated a statistically significant pancreatitis-incidence signal in the trial populations — Pattern V direction-of-effect is “no established increased risk in trial populations” with the explicit acknowledgment that severe-prior-pancreatitis-history patients were excluded from trial enrollment (§2.4 contraindication).

The cagrilintide-component pancreatitis class-level status is under-characterized; pramlintide ~20-year post-marketing experience has not surfaced a major pancreatitis signal but the exposure pattern is different. REDEFINE program adjudication included pancreatitis adjudication per Phase 3 standard; population-scale pancreatitis incidence within trial follow-up windows is low.

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class (§6.2) typically does not produce severe persistent localized pain — protocol differentiates “GI AE expected at titration” from “pancreatitis-suspect abdominal pain” via persistence, severity, localization, and lipase.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue CagriSema pending evaluation.

Escalation triggers. Confirmed acute pancreatitis (clinical + lab + imaging) → hospitalization, supportive management per pancreatitis standard-of-care.

Discontinuation triggers. Confirmed acute pancreatitis attributable to the molecule (excluding alternative etiology — gallstones, hypertriglyceridemia, alcohol) → permanent discontinuation, transition to non-GLP-1-containing alternative if Module 5 indication continues.

6.5 NAION AE class — semaglutide-component signal under evaluation

Anticipatory framing. Non-arteritic anterior ischemic optic neuropathy (NAION) class-differentiated to semaglutide vs tirzepatide per Lakhani et al 2025 Am J Ophthalmol 180-country pharmacovigilance analysis (PMID 40383360). The signal is post-marketing and under active evaluation; EMA semaglutide labeling reflects this class-differentiation as of June 2025; FDA labeling action pending. CagriSema inherits the NAION signal via the semaglutide-component; whether the cagrilintide-component alters this signal is research-state-incomplete (the CagriSema-specific pharmacovigilance dataset is small pre-FDA-approval). Pattern AA precision: counseling beats (§10) frame this as “signal under evaluation; absolute risk in the population studied was small; clinician judgment in patients with disc-at-risk anatomy or prior NAION applies.”

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential includes giant cell arteritis (arteritic AION, separate entity), retinal vascular occlusion, optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue CagriSema pending evaluation. Cross-reference with ESR/CRP to rule out arteritic etiology.

Escalation triggers. Confirmed NAION → permanent discontinuation, ophthalmology co-management, consideration of contralateral-eye risk.

Discontinuation triggers. Confirmed NAION → permanent discontinuation regardless of indication continuation; transition to non-semaglutide Module 5 alternative. Tirzepatide (FDA-approved single-molecule GLP-1/GIP coagonist) is the most-established alternative with class-differentiated signal-absent profile per Lakhani 2025.

6.6 Diabetic retinopathy AE class — REDEFINE-2 indication specifically

Anticipatory framing. Class-level consideration for GLP-1 RA in T2D populations with pre-existing retinopathy. Rapid glycemic improvement worsens retinopathy in some patients per SUSTAIN-6 documentation. REDEFINE-2’s substantive HbA1c reduction places CagriSema in the rapid-glycemic-improvement risk profile. The signal is anchored to advanced background or proliferative DR with rapid glycemic improvement, not to all CagriSema T2D patients.

Identification. Pre-treatment dilated exam (§3.6); annual dilated exam in maintenance for T2D patients with any baseline DR; symptom-prompted evaluation for visual changes.

First-line management. Ophthalmology co-management for any progression; pace of glycemic improvement is dose-driven (CagriSema dose-down to 1.8/1.7 mg or 1.2/1.0 mg may slow glycemic improvement if retinopathy progression is occurring at rapid pace).

Discontinuation triggers. Severe DR progression attributable to rapid glycemic improvement → ophthalmology-co-managed discontinuation decision; alternative T2D regimen with slower glycemic improvement may be appropriate.

6.7 Hypoglycemia AE class (T2D indication with concurrent insulin or sulfonylurea)

Anticipatory framing. CagriSema components are non-insulin-secretagogue (glucose-dependent insulin-secretion mechanism of semaglutide-component is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents; cagrilintide-component does not stimulate insulin secretion). Hypoglycemia risk emerges when CagriSema is combined with insulin or sulfonylurea. The pivotal-trial protocol approach: reduce concurrent agent dose at initiation (insulin typically reduced approximately 20% at GLP-1 RA initiation; sulfonylurea typically reduced approximately 50% or discontinued).

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target.

First-line management. Reduce concurrent insulin or sulfonylurea dose. CGM titration where available. Hypoglycemia recognition and treatment counseling reinforcement.

Discontinuation triggers. Hypoglycemia from CagriSema mechanism is not a discontinuation indication for CagriSema; it is a dose-adjustment indication for the concurrent agent.

6.8 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) occur in low single-digit percent of patients on weekly subcutaneous GLP-1 RA-containing pens; usually mild and self-resolving. Lipohypertrophy can develop with site rotation failure.

Identification. Patient-reported or visit-observed. Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly). Topical hydrocortisone for pruritus.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a labeled contraindication (§2.4) and triggers permanent discontinuation.

6.9 Cardiovascular AE class

Anticipatory framing. Class-level small heart rate increase (~2–3 bpm) consistent with the GLP-1 RA class via the semaglutide-component. Blood pressure reduction in maintenance phase is anticipated (substantive weight-loss-mediated effect + direct semaglutide-component effects + small cagrilintide-component effects). MACE outcomes pending REDEFINE-3 readout; CagriSema does NOT have a CV-risk-reduction indication as of 2026-05-13.

Identification. Heart rate at every maintenance visit; BP at every maintenance visit; symptom-prompted CV evaluation.

First-line management. Heart rate increase typically tolerated and does not require intervention; concomitant β-blocker if pre-existing tachycardia. BP improvement allows down-titration of antihypertensive co-medication in some patients (clinician judgment; monitor for over-correction → orthostatic hypotension).

6.10 Worked example — CagriSema AE management

Patient C (worked example — pancreatitis on REDEFINE-2 indication). A T2D adult on CagriSema 2.4/2.4 mg, Month 4, presents with acute severe upper abdominal pain radiating to back, vomiting, hospitalized in ED. Lipase elevated to 5× upper limit normal; abdominal CT shows mild peripancreatic fat stranding without necrosis. Triglycerides 220 mg/dL (not severely elevated). No gallstones on imaging. No alcohol history.

Protocol response. Confirmed acute pancreatitis; alternative etiologies ruled out — CagriSema-attributable acute pancreatitis is the working diagnosis. Discontinue CagriSema. Supportive pancreatitis management per standard of care. Permanent discontinuation of CagriSema post-recovery; transition to non-GLP-1-containing T2D regimen — consider SGLT2 inhibitor (if not already on), pioglitazone, or insulin per ADA/EASD T2D-progression algorithm. Counsel on T2D-progression and weight-management context post-CagriSema.

Patient G (worked example — NAION). A non-T2D adult on CagriSema 2.4/2.4 mg, Month 4 on target dose, develops acute painless monocular vision loss in left eye over approximately 24 hours. Ophthalmology urgent evaluation confirms left optic disc edema with altitudinal visual field defect; ESR and CRP normal (excluding GCA). Diagnosis: NAION, left eye.

Protocol response. Discontinue CagriSema. Confirmed NAION → permanent CagriSema discontinuation. Ophthalmology co-management for fellow-eye monitoring (post-NAION fellow-eye recurrence is the established counseling beat). Module 5 indication continuation: discuss with patient — for CWM indication, tirzepatide is not contraindicated on NAION grounds (Lakhani 2025 documented class-differentiation with signal-absent for tirzepatide); Pattern V flag — the patient and clinician decide whether to attempt tirzepatide or transition to non-GLP-1 weight-management approach.

Patient F (worked example — AE-emergent dose-down, recapitulated from §5.5). 62-year-old female on CagriSema 2.4/2.4 mg for non-T2D CWM, Month 5 on maintenance, persistent Grade 2 nausea with unintended weight loss below patient’s target floor. Dose-down to 1.8/1.7 mg. Pattern Z calibration: patient-preference-anchored, not clinician-mandated.

Pattern AA precision in §6.10. “Pancreatitis-attributable to CagriSema” is precise (alternative etiologies ruled out; temporal association); anticipated CagriSema labeling for pancreatitis is “precaution / labeled cautionary use” per class convention, not “labeled contraindication” — but post-event, permanent discontinuation is the clinical judgment standard. “NAION signal” is precise — post-marketing pharmacovigilance for the semaglutide-component, not labeled warning at FDA level as of 2026-05-13 (EMA-labeled for semaglutide); management response (discontinuation) is clinician-judgment alignment with signal-direction precaution.

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when CagriSema’s primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). §7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau (apparent stall that is normal-trajectory variation) from true plateau (legitimate response stall requiring intervention) and from non-response (insufficient initial effect from the start).

7.2 Pseudo-plateau vs true plateau vs non-response

Pseudo-plateau. Apparent stall in weight or HbA1c within normal week-to-week or month-to-month variation, or reflecting body-composition change (lean-mass preservation with fat-mass continued loss) rather than total-weight stall, or occurring in the predictable trial-trajectory pattern (most weight-loss molecules show deceleration in months 6–9 even on continued effective therapy; REDEFINE-1 and -2 curves show this pattern). Pseudo-plateau recognized by trajectory-context against the REDEFINE-1 / REDEFINE-2 median curve for the patient’s phenotype.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. Recognized by trajectory inflection plus an adequate observation window (typically 2–3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3–6 on target dose with effect substantially below the REDEFINE-1 or REDEFINE-2-anchored trajectory for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. CagriSema’s high-tier effect-size (REDEFINE-1 22.7%; REDEFINE-2 −13.7%) drives weight loss into new set-point territory; loss beyond the body’s defended range recruits counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis). True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in counseling (§10) does not pathologize plateau but reframes it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

7.4 Decision tree for plateau / non-response

1. Confirm adherence. Missed doses, injection-technique issues, pen-storage issues (cold-chain compliance) are common pseudo-non-response causes. Confirm via patient interview and prescription-refill audit.

2. Confirm trajectory-context. Plot the patient’s curve against the REDEFINE-1 (non-T2D) or REDEFINE-2 (T2D + obesity) median curve. If the curve is on-trajectory, pseudo-plateau — continue current dose, reassess at next interval.

3. Confirm dose attainment. Is the patient on 2.4/2.4 mg target dose? If not, complete titration to target dose; reassess at Month 3 on target.

4. Reassess phenotype. Does the patient’s clinical picture support the REDEFINE-enrolled phenotype, or is the patient in an under-represented or out-of-trial phenotype? Pattern V direction-of-effect — for under-represented phenotypes (e.g., BMI 27–30 in a non-T2D patient without comorbidities meeting REDEFINE-1 enrollment, which is outside REDEFINE-1 enrollment), expected effect-size may be smaller, recalibrate target.

5. If true plateau / non-response confirmed at adequate observation window:

   • CWM context (REDEFINE-1-anchored, no T2D): consider transition to tirzepatide (SURMOUNT-1 effect-size approximately 22.5% at 15 mg vs CagriSema REDEFINE-1 22.7% — similar effect-size tier descriptively; no head-to-head exists; the choice is anchored on the patient’s individual-context tolerability and on cost / access). Consider transition to retatrutide once approved (TRIUMPH-1 readout in obesity per Rosenstock 2025 NEJM PMID 40454039). Consider intensification of behavioral / nutritional / activity program (STEP-3-class evidence supports IBT additivity to GLP-1 RA effect).

   • CWM + T2D context (REDEFINE-2-anchored): transition to tirzepatide (SURPASS-2 head-to-head establishes tirzepatide 15 mg HbA1c reduction approximately 2.3% vs semaglutide 1 mg approximately 1.9% at Week 40); add SGLT2 inhibitor if not already on (additive CV / kidney benefit); add insulin per ADA/EASD progression algorithm if T2D progressing.

   • High-tier weight-loss-targeting context: the maximum-tier effect-size compounds (CagriSema, tirzepatide 15 mg, retatrutide once approved, semaglutide 7.2 mg per STEP UP) are descriptively similar at population-level; individual-patient response within and across compounds varies; failure on one maximum-tier compound does not predict failure on another but does inform tolerability and adherence patterns.

   • Metabolic / behavioral surgery consideration. Sleeve gastrectomy and Roux-en-Y gastric bypass remain the highest-magnitude weight-loss intervention (~25–30% sustained); for patients with CagriSema non-response and severe-comorbid obesity, surgical consultation is appropriate.

7.5 Worked example — CagriSema non-responder algorithm

A non-T2D adult on CagriSema 2.4/2.4 mg, Month 6 on target dose, has lost 5.5 kg from baseline (approximately 5% of starting weight) — well below the REDEFINE-1 median trajectory at Month 6 (which trends toward 22.7% endpoint at Month 17 / Week 68 with most weight loss accruing by Month 9).

Algorithm walkthrough.

Step 1 — adherence. Patient reports 100% adherence; prescription-refill audit confirms no gaps. Adherence-confirmed.

Step 2 — trajectory-context. Patient’s curve at Month 6 (5% loss) is below the REDEFINE-1 median Month 6 trajectory (which is in the 12–15% range at Month 6 by visual reference to published curves). Not on-trajectory.

Step 3 — dose attainment. Patient is on 2.4/2.4 mg target dose; no further titration available within CagriSema labeled dosing.

Step 4 — phenotype reassessment. Patient is a 52-year-old female, BMI 33, no T2D, no comorbidities. Per REDEFINE-1 enrollment, this phenotype is represented (BMI ≥30, no T2D). Phenotype is trial-enrolled and effect-size expectation is approximately 22.7%; patient’s response at Month 6 is below the typical REDEFINE-1 trajectory.

Step 5 — non-response confirmed; CWM-without-T2D decision branches.

5a. Transition to tirzepatide. SURMOUNT-1 effect-size approximately 22.5% at 15 mg in non-diabetic obesity is the trial-anchored alternative. Pattern V direction-of-effect: tirzepatide effect is in the same maximum-tier descriptively; the patient may achieve a clinically meaningful weight loss on tirzepatide that did not materialize on CagriSema — but cross-compound individual response is empirically uncharacterized.

5b. Intensification of behavioral / nutritional / activity program. Per STEP-3-class evidence on IBT additivity to GLP-1 RA effect. Patient may achieve additional weight loss with intensive behavioral therapy in conjunction with continued CagriSema before considering molecule transition.

5c. Reassess for unrecognized contributors to non-response. Stress / sleep / behavioral factors; concurrent medication with weight-gain effect (corticosteroids, atypical antipsychotics, some antidepressants); concurrent medical condition (hypothyroidism — TSH recheck if borderline; Cushing’s — clinician judgment for cortisol workup).

Pattern Z calibration anchor 4 + 5 applied at §7.5. The decision among 5a / 5b / 5c is patient-anchored, not clinician-mandated. Counseling beats (§10) frame the options without steering — present the trial-program-anchored effect-size estimates for each option, present the trade-offs (cost, AE-profile, adherence-complexity), and the clinician-patient decision is patient-preference-driven within the medically reasonable options.

8. Discontinuation and tapering

8.1 Purpose

Define when to stop CagriSema, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory. §8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

8.2 When to discontinue — discontinuation triggers

Discontinuation is indicated when one of the following emerges:

• Confirmed contraindication discovery (e.g., new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM indication). §2.4 hard contraindications are immediate-discontinuation triggers.
• Severe AE attributable to the molecule (confirmed acute pancreatitis, confirmed NAION, severe hypersensitivity reaction). §6 AE-class-specific discontinuation triggers.
• Indication remission or resolution (rare in CWM at this time-scale; T2D HbA1c sustained below target with weight stable in some patients).
• Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway.
• Cost / access barriers. A documented practice-level reality, particularly for a combo product at premium pricing in a market with established single-mechanism alternatives. Pattern Z calibration anchor 1+2 framing applies in §10 — present the cost / access reality factually, not as steering.
• Pre-conception planning for reproductive-age patients: discontinuation with ~35-day washout per the §8.4 arithmetic. Anticipatory, not reactive.
• Maximum-tolerable-dose non-response per §7 algorithm with transition to alternative pharmacology or to non-pharmacologic pathway.

8.3 How to taper — combo-product-specific considerations

For CagriSema combo product: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — both components have ~7-day half-lives and pharmacokinetic clearance occurs at fixed kinetics regardless of taper schedule. However, gradual dose reduction is the protocol-recommended pattern for two reasons:

1. Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation (the patient’s reduced appetite signal returns gradually, allowing meal-size and meal-composition adaptation in parallel).

2. AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these.

Typical CagriSema taper: 2.4/2.4 mg → 1.8/1.7 mg × 4 weeks → 1.2/1.0 mg × 4 weeks → 0.6/0.5 mg × 4 weeks → discontinue. Total taper period approximately 12 weeks. Both components step down synchronously (the combo pen at each titration step is the operational delivery). This is clinician-judgment within anticipated label.

No taper — abrupt discontinuation appropriate in specific scenarios: confirmed pancreatitis (§6.4); confirmed NAION (§6.5); severe hypersensitivity reaction; transition to alternative GLP-1 RA-containing therapy where immediate replacement is the operational pattern.

8.4 Pre-conception washout arithmetic

Both components have ~7-day elimination half-lives (synchronous). Approximately 5 half-lives are required for >95% pharmacokinetic clearance — approximately 5 weeks for both components, i.e., approximately 35 days for both. Anticipated CagriSema labeling will follow class convention with an 8-week pre-conception window recommendation (the pharmacokinetic minimum + pharmacodynamic clearance + margin).

This 8-week pre-conception window is the operational counseling beat for reproductive-age patients on CagriSema. §10 carries the Pattern Z calibration anchor 3 (pregnancy planning) precision: lead with Parker et al 2025 Reprod Toxicol (PMID 40329607) pooled regulatory pregnancy-exposure data covering the semaglutide-component within GLP-1 RA class (incidence of congenital abnormalities relatively low in pooled dataset; sample size limited; prospective planned-pregnancy data research-state-incomplete). Pharmacokinetic facts and label recommendation follow the research-state lead.

8.5 Post-discontinuation weight-regain framing

CagriSema-specific post-discontinuation weight-regain trajectory data accrues post-approval. Class-context anchors the framing:

• STEP-4 (semaglutide 2.4 mg maintenance vs placebo-switch in patients who had achieved weight loss on semaglutide; Rubino DM et al 2021 JAMA PMID 33755728; NCT03548987): discontinuation after target-dose achievement is followed by progressive weight regain across approximately 12 months, with patients regaining a substantial fraction of the lost weight by 12 months post-discontinuation.
• SURMOUNT-4 (tirzepatide maintenance vs placebo-switch): similar pattern.

CagriSema discontinuation-regain trajectory is anticipated to follow the class pattern (post-discontinuation, the body’s counter-regulatory responses re-establish a higher equilibrium). Patient framing in §10 does not pathologize regain; frames the regain trajectory as expected biological response.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: typically re-titration from the starting dose (0.3/0.25 mg Week 1) is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior target dose is not recommended due to GI AE recurrence risk. §4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2, and pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

8.7 Worked example — CagriSema discontinuation scenarios

Scenario A — pre-conception planning. A 32-year-old female on CagriSema 2.4/2.4 mg, Month 14 on target dose, has lost 18 kg (approximately 18% of starting weight, on-trajectory for REDEFINE-1 effect-size) and is planning conception in approximately 6 months. Counseling beat: discuss the 8-week pre-conception window per anticipated label; plan taper start approximately 5 months from now (12-week taper period; then ~8-week post-discontinuation pharmacokinetic-and-margin window). Pattern Z calibration anchor 3 applies — pregnancy-planning counseling LEADS with Parker 2025 human pregnancy-exposure pooled data for the semaglutide-component, then presents the pharmacokinetic facts (1-week half-life for both components, 35-day pharmacokinetic clearance, 8-week recommendation), then the post-discontinuation weight-regain trajectory.

Scenario B — patient-preference discontinuation at Month 18. A 58-year-old male on CagriSema 2.4/2.4 mg, has lost 17 kg (approximately 16% of starting weight) and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue. Counseling beat: discuss class-context discontinuation-regain trajectory (STEP-4 / SURMOUNT-4); CagriSema-specific data accrues post-approval; re-initiation pathway is available if regain occurs and is clinically meaningful. Protocol taper: 2.4/2.4 mg → 1.8/1.7 mg × 4 weeks → 1.2/1.0 mg × 4 weeks → 0.6/0.5 mg × 4 weeks → off. Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP.

Scenario C — confirmed acute pancreatitis (per §6.10 case). Permanent discontinuation. No taper — abrupt discontinuation appropriate given AE-attributable etiology. Transition to non-GLP-1 alternative per indication.

Scenario D — new pregnancy on protocol. A 29-year-old female on CagriSema 2.4/2.4 mg discovers pregnancy at approximately 6 weeks gestation. CWM-indication CagriSema is anticipated labeled contraindication in pregnancy. Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (~35 days, with first-trimester exposure already occurred) is documented for the obstetrics record. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

Pattern Z calibration anchor 3 precision in §8.7. Pregnancy-planning counseling LEADS with Parker 2025 human pooled pregnancy-exposure data for the semaglutide-component class. Pharmacokinetic facts and label recommendation appear AFTER the research-state lead. Animal data and Category-X-equivalent framing relegated to scoped factual context. The patient’s reproductive-planning decision is patient-anchored.

9. Combination rules

9.1 Purpose

Define what stacks with CagriSema, what is contraindicated in combination, and the rationale for each combination category. §9 is the protocol’s bridge to Module 5.12 Combination Protocols and to the lean-mass-stack protocols. The section is structured by combination class — within-Module-5 combinations (with class-context to alternative GLP-1 RA-containing therapies); cross-Module combinations (lean-mass peptides; cross-class anti-obesity agents); contraindicated combinations.

Pattern W cross-section consistency: every combination is reconciled with §2 (no combination includes an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate §6 AE-class concerns), and §10 (combination counseling beats are Pattern Z calibration-anchor-compliant).

Important structural note. Because CagriSema is already a fixed-dose combination product (cagrilintide + semaglutide), the within-Module-5 “combinations” discussed here are combinations of CagriSema with additional non-overlapping mechanism-class agents, not combinations of CagriSema with single-mechanism GLP-1 RAs or amylin analogs (which would be redundant and contraindicated — §9.4).

9.2 Within-Module-5 combinations — CagriSema plus complementary mechanism class

CagriSema + SGLT2 inhibitor (T2D indication context). Class-additive HbA1c, cardiovascular, and kidney benefits. CagriSema’s substantive HbA1c effect (REDEFINE-2 demonstrated) combines with SGLT2 inhibitor glucose-osmotic-diuretic and ketogenesis-modulating effects. Mechanism rationale: SGLT2 inhibitor mechanism is non-overlapping with both CagriSema components; the combination is broadly supported by individual-agent CVOT and KOOT data and by clinical-practice cohort analyses. For polycondition patients (T2D + ASCVD + CKD), this is the standard polycondition regimen. Pattern V direction-of-effect: combination effect-additive on HbA1c and on kidney composite per individual-agent data; head-to-head combination RCT not yet conducted for CagriSema specifically; individual-agent CVOT (SELECT for semaglutide-component; FLOW for kidney; EMPA-KIDNEY/DAPA-CKD for SGLT2) supports the directional anchor.

CagriSema + metformin (T2D indication context). Foundational T2D therapy; class-additive. Metformin continued at standard dose during CagriSema initiation and maintenance for most T2D patients.

CagriSema + insulin (T2D advanced). Common in T2D with progressed beta-cell failure where non-insulin pharmacology is insufficient. §6.7 hypoglycemia management applies; concurrent insulin dose typically reduced approximately 20% at CagriSema initiation, with further reduction during titration as glycemic improvement accrues.

CagriSema + DPP-4 inhibitor: NOT indicated. DPP-4 inhibitor preserves endogenous GLP-1; redundant with the exogenous GLP-1 RA semaglutide-component of CagriSema. Avoid co-prescribing. If patient is on DPP-4 inhibitor and transitions to CagriSema, discontinue DPP-4 inhibitor.

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations add a peptide outside the metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss.

CagriSema + CJC-1295 / Ipamorelin (GH secretagogue stack). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. CagriSema’s high-tier weight-loss effect-size (REDEFINE-1 22.7%; REDEFINE-2 −13.7%) makes lean-mass preservation a relevant clinical concern, particularly in older adults and high-baseline-lean-mass patients. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, monitoring (IGF-1 anchored), and AE-class considerations. Pattern AA precision: this is off-label / clinician-judgment within informed-consent for the GH-secretagogue components; CagriSema itself is investigational pre-approval; the combination is mechanism-rationale-supported and M5.6-cohort-supported, not Phase-3-validated.

CagriSema + Tesamorelin (FDA-approved for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with CagriSema-mediated weight loss, visceral-adiposity-targeted effects are additive. Off-label for non-HIV visceral adiposity per clinician judgment.

CagriSema + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data; clinician judgment within Module 5.6 stack framing. Pattern AA precision: investigational, not approved.

9.4 Contraindicated combinations

• CagriSema + concurrent semaglutide standalone (Wegovy/Ozempic/Rybelsus). Redundant within-molecule — the semaglutide-component of CagriSema is the same molecule. Concurrent administration produces overlapping exposure with no demonstrated additive benefit and additive AE burden. If patient is on semaglutide standalone and transitions to CagriSema, discontinue semaglutide standalone at CagriSema initiation (§8.8 switching considerations).

• CagriSema + concurrent cagrilintide standalone (if cagrilintide standalone is available pre-approval through investigational pathways). Same redundancy issue.

• CagriSema + concurrent tirzepatide. Within-class redundant mechanism on the GLP-1R axis (tirzepatide is a GLP-1/GIP coagonist; CagriSema contains the GLP-1 RA semaglutide-component). Additive AE profile with no demonstrated additive benefit; head-to-head transition decision, not co-administration.

• CagriSema + concurrent retatrutide. Same within-class redundancy on the GLP-1R axis (retatrutide is a GLP-1/GIP/glucagon triagonist).

• CagriSema + DPP-4 inhibitor (§9.2 — not contraindicated by safety; contraindicated by redundancy and lack of additive benefit).

• CagriSema + sulfonylurea at full sulfonylurea dose (relative — combination produces excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at CagriSema initiation per §6.7).

• CagriSema + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile and may impair absorption of concurrent oral medications).

9.5 Switching considerations — adapted from §8.8 of canonical

From single-agent semaglutide 2.4 mg (Wegovy) to CagriSema. Patients on stable semaglutide 2.4 mg may transition to CagriSema with the cagrilintide-component addition. The semaglutide-component dose is unchanged (2.4 mg → 2.4 mg); the cagrilintide-component is added through titration. Two operational approaches:

• (a) Direct switch to CagriSema starting at the Week 13–16 step (1.8 mg cagrilintide + 1.7 mg semaglutide): semaglutide-component dose slightly stepped down (2.4 → 1.7 mg for the 4-week step) but the patient is already adapted to GLP-1 RA mechanism; cagrilintide-component titrated up through the remaining step to 2.4/2.4 mg maintenance. Operationally simpler if patient is tolerating semaglutide 2.4 mg well. Pattern AA precision: this is clinician-judgment off-label / off-anticipated-label until FDA action; the Phase 3 protocol started naive patients at 0.3/0.25 mg.

• (b) Re-titrate both components from start (0.3/0.25 mg Week 1): operationally more conservative; allows full GI AE re-evaluation with combo. Disadvantage: substantial step-down in semaglutide-component dose during the early titration steps may produce some weight-regain pulse before re-attaining target dose.

The optimal switching protocol per anticipated FDA labeling at approval; current Phase 3 evidence base is for naive-patient initiation at 0.3/0.25 mg.

From tirzepatide (Mounjaro/Zepbound) to CagriSema. Mechanism class switch (tirzepatide GLP-1/GIP coagonist → CagriSema GLP-1 + amylin combo); no direct switching protocol Phase-3-validated. Clinical practice would involve discontinuation of tirzepatide + appropriate washout (~5 half-lives ≈ 25 days for tirzepatide) + initiation of CagriSema at the 0.3/0.25 mg starting dose with full 16-week titration. Patient counseling on different mechanism class + different AE profile expectations + the temporary weight-regain pulse during the washout-and-restart-titration period.

From CagriSema to alternatives. Discontinuation of CagriSema involves combo discontinuation per §8; class-context weight-regain trajectory applies; alternative pharmacotherapy initiation per patient preference + clinical context (tirzepatide; retatrutide once approved; semaglutide standalone if patient prefers single-mechanism after CagriSema experience).

9.6 Worked example — CagriSema combination scenarios

Scenario A — CagriSema 2.4/2.4 mg + CJC-1295 / Ipamorelin stack (M5.6 v3). A 47-year-old male, baseline BMI 36, on CagriSema 2.4/2.4 mg, Month 8 on target dose, has lost 18 kg with DEXA showing approximately 32% of lost mass as lean mass (above the 20–25% typical proportion for unsupplemented weight loss). Add M5.6 v3 stack — CJC-1295 + Ipamorelin per the M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly. Pattern Z calibration anchor 5 (off-label / extrapolation transparency) applies — counseling beat states explicitly that CagriSema is itself investigational pre-approval, and that CJC-1295 and Ipamorelin are not FDA-approved for this indication, and that the combination is supported by mechanism rationale plus M5.6 v3 clinical-practice cohort, not by Phase 3 RCT data.

Scenario B — CagriSema + SGLT2 inhibitor (T2D advanced). A 61-year-old male with T2D + CKD eGFR 42, on CagriSema 2.4/2.4 mg (REDEFINE-2-anchored indication) with HbA1c 7.4 (above individualized target 7.0); add empagliflozin 10 mg daily per ADA/EASD T2D-progression algorithm. Combination is well-supported by individual-agent CVOT / KOOT data and by additive HbA1c reduction. Monitoring: eGFR at 2 weeks post-SGLT2 initiation (typical small reversible eGFR decline expected), then routine quarterly. Pattern V direction-of-effect: combination is effect-additive on HbA1c and kidney composite per individual-agent data; cross-class combination supported by clinical-practice and individual-agent trial data.

Scenario C — CagriSema + tirzepatide concurrent (contraindicated). A patient seeking dual-class metabolic intensification. Counseling beat: combination not indicated — these are within-class redundant agents on the GLP-1R axis; transition between them (§7 non-response algorithm) is the appropriate decision, not co-administration. Effect-size context: cross-trial descriptive comparison (REDEFINE-1 CagriSema 22.7% vs SURMOUNT-1 tirzepatide 22.5%) places these in the same maximum-tier; the within-class redundancy on GLP-1R agonism makes co-administration mechanistically inappropriate.

Scenario D — CagriSema + concurrent compounded semaglutide (contraindicated). A patient on CagriSema receiving compounded semaglutide separately (perhaps unaware of the redundancy or with a separate clinician). Counseling beat: discontinue the compounded semaglutide. Concurrent administration produces redundant semaglutide exposure with additive AE burden; this is a Pattern Z anchor 2 + Pattern AA precision issue — the patient may have received the compounded semaglutide on the assumption it was complementary to CagriSema, but the semaglutide-component of CagriSema is the same molecule.

Pattern W cross-check at §9.6. Each combination above is reconciled with §2 (no combination includes a contraindicated agent), §6 (combination AE-management does not mask individual-agent AE algorithms), and §10 (combination counseling beats are Pattern Z calibration-anchor-compliant).

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define CagriSema’s patient-counseling content. §10 is the operational anchor for Pattern Z (cumulative-tone calibration), Pattern R (lead-framing calibration), and Pattern AA (regulatory-claim precision); counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

The five Pattern Z calibration anchors (anchors 1–5 per /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md) apply with combo-product-specific adaptations from the CagriSema canonical §12.10 patient-discourse triage:

• Anchor 1 — Lead with what the option IS.
• Anchor 2 — Compounded vs FDA-approved framing (special CagriSema treatment: compounded CagriSema is operationally improbable; the meaningful Anchor-2 framing for CagriSema involves compounded semaglutide-component-only, not compounded CagriSema combo).
• Anchor 3 — Pregnancy-planning precision (LEADS with Parker 2025 human pregnancy-exposure data via the semaglutide-component class).
• Anchor 4 — Multi-dimensional comparator framing (CagriSema vs tirzepatide vs semaglutide standalone vs retatrutide vs IcoSema).
• Anchor 5 — Off-label / extrapolation transparency — adapted for CagriSema as investigational (pre-approval), not off-label (off-label requires an approved label).

10.2 Initiation conversation (§4 anchor)

The initiation conversation occurs at the pre-treatment workup completion / §4 initiation visit. Required counseling beats:

• What CagriSema is (Anchor 1): name, class, mechanism in plain-language. “CagriSema combines two long-acting peptides — cagrilintide, an amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist — into a single weekly injection. The two work together: cagrilintide acts primarily on satiety circuits in the brainstem to reduce meal size and slow gastric emptying; semaglutide acts on GLP-1 receptors in the brain and pancreas to reduce appetite and improve glycemic control. Combining them produces more weight loss than either single component alone.”

• Regulatory state precision (Anchor 5 adapted): “CagriSema is not yet FDA-approved. The Phase 3 program — REDEFINE — has read out and Novo Nordisk has filed the regulatory dossier; FDA review is ongoing. Current clinical use is investigational. The reason we can talk about it as a clinical option now is that the Phase 3 evidence base is substantive and the regulatory pathway is in motion; the reason it isn’t routinely available for prescription is that FDA action is pending. For your situation, current options include enrollment in active REDEFINE trials, off-label co-administration through investigational pathways for cagrilintide (operationally constrained), or waiting for FDA approval if your clinical context allows the delay. Once approved, the protocol I’m describing is what we’d follow.”

• Effect-size with trial-anchor precision (Anchor 1 + Pattern V):

  • For REDEFINE-1-anchored CWM-without-T2D: “REDEFINE-1 randomized 3,417 adults with obesity (BMI ≥30 or ≥27 with weight-related comorbidity) to one of four arms: CagriSema combo, cagrilintide alone, semaglutide alone, or placebo. At 68 weeks, the CagriSema arm lost about 22.7% of body weight on average; about 40% of participants achieved 25% or more weight loss. The cagrilintide-alone arm was about 11.8%; the semaglutide-alone arm was about 16.1%; the placebo arm was about 2.3–3.0%. For your phenotype, the REDEFINE-1 effect-size is the trial-anchored estimate.”
  • For REDEFINE-2-anchored CWM-with-T2D: “REDEFINE-2 randomized 1,206 adults with obesity plus T2D (BMI ≥27 + T2D) in a 3-to-1 ratio to either CagriSema or placebo — 904 to CagriSema, 302 to placebo. At 68 weeks, the CagriSema arm lost about 13.7% of body weight; the placebo arm lost about 3.4%. The treatment difference is about 10.4 percentage points favoring CagriSema, with a 95% confidence interval of −11.2 to −9.5 percentage points, P less than 0.001. The trial was placebo-controlled, not a head-to-head versus other GLP-1 medications. HbA1c also improved substantively in the CagriSema arm. For your phenotype with obesity plus T2D, the REDEFINE-2 effect-size is the trial-anchored estimate.”

• The titration schedule (§4): standard 16-week pace and slow-titration option; the patient is informed that the titration timeline is adjustable to their tolerability.

• The AE profile expected at each titration step (§6 GI class anticipatory framing): combo-additive GI AE burden — both components contribute; the 16-week titration is designed to enable tolerance development.

• The pre-conception planning beat for reproductive-age patients (Anchor 3): see §10.4.

• Cost / access realities (Anchor 2): see §10.3.

• What the patient signals back if any concern emerges (escalation pathway): symptoms that warrant in-person evaluation within 48 hours (severe persistent abdominal pain, vomiting blood, acute vision change, signs of severe AE).

10.3 Compounded vs FDA-approved counseling (Anchor 1 + 2 — CagriSema-specific adaptation)

The Anchor 1 + 2 framing for CagriSema is structurally distinct from semaglutide-standalone or tirzepatide-standalone Anchor 2 framing because compounded CagriSema as a single co-formulated product is operationally improbable. Cagrilintide is pre-FDA-approval; the FDA-shortage-declaration pathway under 503A/503B does not apply; compounding pharmacies cannot legally compound non-FDA-approved drugs except for limited research/clinical-trial purposes. §10.3 of this protocol takes the light Pattern Z treatment per the Methodology Adaptation Memo Q5 Option B resolution.

Pattern Z compliant framing for CagriSema specifically. “Compounded CagriSema as a single formulation isn’t widely available because cagrilintide is pre-FDA-approval — there’s no FDA-shortage pathway for cagrilintide the way there is for semaglutide. If you’re considering compounded alternatives to FDA-approved obesity therapies, what’s actually available through 503A/503B compounding-pharmacy pathways during shortage periods is compounded semaglutide alone — which is a single-mechanism GLP-1 RA therapy, not a combo amylin + GLP-1 therapy. Let’s discuss what you’re hoping to achieve and whether compounded semaglutide alone, FDA-approved Wegovy (or Ozempic for T2D), FDA-approved tirzepatide (Zepbound for CWM; Mounjaro for T2D), or waiting for CagriSema FDA approval is the right fit. Each has trade-offs.”

§10.3 is N/A pre-approval for compounded CagriSema as a single product. Per Anchor 5 dominant pre-approval framing (per task instructions), the §10 counseling beat for “compounded CagriSema” framing is: there is no compounded CagriSema combo product; offerings under that name are most likely compounded semaglutide alone, co-administered separate compounded peptides (with cagrilintide via research-chemical pathway, which is operationally and regulatorily distinct from drug-compounding), or misrepresented products. Patient should evaluate any “compounded CagriSema” offering against this structural reality before considering it.

10.4 Pregnancy-planning conversation (Anchor 3)

For reproductive-age patients on CagriSema. The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or label recommendation.

• Human pregnancy-exposure data — Parker et al 2025 (PMID 40329607). Pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size limited; exposures from unplanned-pregnancy contexts. Prospective planned-pregnancy exposure data is research-state-incomplete; authors call for prospective pregnancy registries. The Parker 2025 dataset is class-level for GLP-1 RA via the semaglutide-component. The cagrilintide-component pregnancy-exposure dataset is smaller (cagrilintide standalone is pre-FDA-approval; pramlintide adjacent-class has 20-year post-marketing experience with limited pregnancy-exposure characterization; CagriSema combo-product pregnancy-exposure data is limited to REDEFINE program unplanned-pregnancy reporting).

• Pharmacokinetic facts (post-research-state-lead). Both components have approximately 1-week half-life (synchronous); approximately 5 half-lives (approximately 35 days) for >95% pharmacokinetic clearance.

• Anticipated label recommendation (Pattern AA pre-approval framing): per class convention, anticipated discontinuation at least 8 weeks before planned conception per anticipated CagriSema label (class-convention pre-conception window).

• Animal data context. Reproductive toxicity studies in animals supported the GLP-1 RA class Category X-equivalent contraindication for the semaglutide-component. Cagrilintide-component animal reproductive toxicity data per Novo Nordisk regulatory submission. Animal data does not always translate to human teratogenicity profile; Parker 2025 human pooled data is the load-bearing human evidence for the semaglutide-component class as of 2026-05-13; CagriSema-specific human pregnancy-exposure evidence base accruing post-approval.

• Post-discontinuation weight-regain trajectory. STEP-4 / SURMOUNT-4 class-context data; CagriSema-specific data accrues post-approval.

• The patient’s reproductive-planning decision is patient-anchored. Some patients will plan conception within the next 1–2 years; some within the next decade; some are not planning conception but want awareness of the protocol-discontinuation arithmetic. The counseling beat presents the facts; the timing decision is patient-anchored.

• Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met.

10.5 Comparator conversation (Anchor 4)

For patients with within-class alternatives — most commonly CagriSema vs tirzepatide vs semaglutide standalone vs (once approved) retatrutide. Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions — single-dimension comparison (weight magnitude alone) is the canonical anti-anchor.

Multi-dimensional comparator fact presentation for CagriSema:

• Regulatory state. CagriSema is investigational pre-FDA-approval (REDEFINE Phase 3 readout complete, NDA filed, FDA review ongoing). Tirzepatide is FDA-approved (Mounjaro for T2D; Zepbound for CWM). Semaglutide standalone is FDA-approved (Wegovy for CWM; Ozempic for T2D; Rybelsus for oral T2D; with MASH and CKD-in-T2D label expansions per ESSENCE and FLOW). Retatrutide is investigational pre-FDA-approval (TRIUMPH-1 readout per Rosenstock 2025 NEJM PMID 40454039). Pattern AA precision: regulatory state differs substantively across these comparators.

• Weight-loss magnitude (Pattern V trial-anchored, cross-trial descriptive). REDEFINE-1 CagriSema 22.7% body-weight reduction in non-T2D obesity at 68 weeks (Garvey 2025); SURMOUNT-1 tirzepatide 15 mg −20.9% TR estimand (PRIMARY ITT) / −22.5% efficacy estimand at 72 weeks (Jastreboff 2022 NEJM PMID 35658024); STEP-1 semaglutide 2.4 mg −14.9% at 68 weeks (Wilding 2021 NEJM PMID 33567185). SURMOUNT-5 head-to-head tirzepatide vs semaglutide 2.4 mg in obesity (Aronne LJ et al 2025 NEJM PMID 40353578; n=751; max-tolerated-dose comparison at week 72): tirzepatide −20.2% vs semaglutide −13.7% — approximately 6.5 percentage-point difference favoring tirzepatide. No CagriSema vs tirzepatide head-to-head trial exists; cross-trial comparison is descriptive only.

• T2D glycemic comparison. REDEFINE-2 CagriSema demonstrated substantive HbA1c reduction vs placebo (−13.7% body weight; HbA1c effect substantive). SURPASS-2 head-to-head T2D: tirzepatide 15 mg approximately 2.3 percentage-point HbA1c reduction vs semaglutide 1 mg approximately 1.9 percentage-point at Week 40.

• Cardiovascular outcomes evidence base. SELECT (Lincoff 2023 NEJM PMID 37952131) for semaglutide CV-risk-reduction in non-diabetic obesity (HR approximately 0.80 for three-point MACE). SURMOUNT-MMO for tirzepatide CV outcomes (in progress, readout pending). REDEFINE-3 for CagriSema CV outcomes (recruiting; readout pending). CagriSema does NOT have a current CV-risk-reduction indication.

• MASH approval status. Semaglutide FDA-approved for MASH F2/F3 per ESSENCE (Sanyal AJ et al 2025 NEJM PMID 40226716); tirzepatide MASH program in development; CagriSema MASH program publicly undisclosed. CagriSema does NOT have a current MASH indication.

• Kidney outcomes evidence base. FLOW (Rossing P et al 2024 NEJM PMID 38078870) for semaglutide kidney-composite reduction in T2D + CKD; tirzepatide kidney outcomes in development; CagriSema kidney program publicly undisclosed. CagriSema does NOT have a current kidney-outcomes indication.

• Ophthalmologic class-differentiation (NAION). NAION signal class-differentiated to semaglutide (signal-present) vs tirzepatide (signal-absent) per Lakhani I et al 2025 Am J Ophthalmol (PMID 40383360). CagriSema inherits signal-present via semaglutide-component; cagrilintide-component effect on signal research-state-incomplete. EMA semaglutide labeling reflects class-differentiation as of June 2025; FDA action pending.

• GI tolerability profile. Both compounds have GI-dominant AE profile. CagriSema has combo-additive GI AE burden (higher than semaglutide alone per REDEFINE-1 4-arm data; higher than placebo per REDEFINE-2 data). Tirzepatide trial-program GI AE incidence is similar-to-modestly-higher than semaglutide single-mechanism; CagriSema vs tirzepatide head-to-head GI tolerability comparison does not exist.

• Route / platform availability. CagriSema: SC injection (single combo pen) only, pending FDA approval. Tirzepatide: SC injection (Zepbound/Mounjaro) only. Semaglutide: SC injection (Wegovy/Ozempic) + oral (Rybelsus 25 mg approved 2025 for T2D).

• Cost and access. CagriSema pricing strategy unknown pre-approval. Combo products typically launch at premium relative to single-mechanism alternatives; insurance coverage at launch typically challenging. Tirzepatide and semaglutide standalone have established pricing with varying insurance coverage. Compounded semaglutide alternatives available via 503A/503B during shortage periods.

• Administration burden. Single weekly injection for all (CagriSema; tirzepatide; semaglutide SC). Rybelsus oral semaglutide is daily with 30-minute fasting window for absorption.

Counseling beat opens with affirmation of both/all compounds, presents the multi-dimensional facts, closes with shared-decision-making invitation: “Both CagriSema (once approved) and tirzepatide are evidence-based weight-management options at similar maximum-effect-size tier. They differ on several dimensions: cardiovascular evidence base where semaglutide has SELECT data and tirzepatide CV trial is in progress; MASH approval where semaglutide is approved and CagriSema’s MASH program isn’t disclosed; NAION class-differentiation where semaglutide and CagriSema carry the signal that tirzepatide doesn’t; insurance coverage and cost which vary and which we won’t know for CagriSema until launch; and GI side-effect profile where combo dosing produces more GI AEs than either single mechanism. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.”

10.6 Investigational / extrapolation conversation (Anchor 5 — DOMINANT pre-approval)

§10 OFF-LABEL DOMINANT pre-approval. Anchor 5 is the dominant Pattern Z anchor for CagriSema as of 2026-05-13. CagriSema is NOT FDA-approved for any indication; therefore any clinical use is investigational, not “off-label” (off-label requires an approved label). The framing distinction is load-bearing for Pattern AA precision.

For patients considering CagriSema pre-approval — whether for the REDEFINE-anchored indications (CWM without T2D; CWM with T2D) or for non-REDEFINE-anchored uses (HFpEF; MASH; CKD; cognitive; off-population micro-uses) — the Anchor 5 counseling beat:

• Explicit investigational framing. “CagriSema is not FDA-approved as of 2026-05-13. The REDEFINE Phase 3 program has read out — REDEFINE-1 in non-T2D obesity and REDEFINE-2 in obesity plus T2D — and Novo Nordisk has filed the regulatory dossier; FDA review is ongoing. Any current clinical use is investigational. This is different from ‘off-label’ use, which requires an approved label for some indication; CagriSema does not have an approved label for any indication.”

• Pre-approval access pathways. Enrollment in active REDEFINE trials (REDEFINE-3 obesity + CVD/CKD; REDEFINE-4 East Asian; REDEFINE pediatric — all recruiting); off-label co-administration of separate components (cagrilintide via investigational supply / research-chemical pathway, operationally constrained; semaglutide via FDA-approved Wegovy/Ozempic/Rybelsus or via 503A/503B compounded during shortage); waiting for FDA approval.

• Primary-source rationale. REDEFINE-1 (Garvey 2025 NEJM PMID 40544433) + REDEFINE-2 (Davies 2025 NEJM PMID 40544432) Phase 3 readouts; ESSENCE / FLOW / SELECT semaglutide-component standalone evidence does not transfer automatically to CagriSema combo for indications outside REDEFINE.

• Informed-consent acknowledgement. Patient understands the use is investigational and consents to clinician judgment within informed-consent standards.

• Re-evaluation if FDA approval emerges. When FDA approval for a CagriSema indication is granted, the use transitions from investigational to label-supported; the counseling beat re-anchors at that transition.

• Trial-population scope precision (Pattern V). REDEFINE-1 enrolled BMI ≥30 or ≥27 with weight-related comorbidity (obesity without T2D); REDEFINE-2 enrolled BMI ≥27 + T2D (obesity with T2D). Effects in lean / metabolically-healthy populations are research-state-uncharacterized; side-effect profile (GI AE, gallbladder events with rapid weight loss, NAION class-signal, pancreatitis class-signal, MTC framework) applies whether the patient is in studied population or not. Population extrapolation outside REDEFINE enrollment is itself a research-state-incompleteness, not an automatic “no” answer — but the safety-profile considerations and effect-size uncertainty must be presented explicitly.

10.7 Discontinuation conversation (§8 anchor)

For patient-preference, indication-resolution, or AE-driven discontinuation. Required counseling beats:

• Reason for discontinuation framing. Patient-preference (legitimate); AE-attribution (clinical decision); pre-conception planning (anticipatory).
• Taper schedule (§8.3): 2.4/2.4 mg → 1.8/1.7 mg × 4 weeks → 1.2/1.0 mg × 4 weeks → 0.6/0.5 mg × 4 weeks → off. Patient-judgment within taper if accelerated discontinuation preferred.
• Post-discontinuation weight-regain framing (§8.5): class-context STEP-4 / SURMOUNT-4 trajectory data; CagriSema-specific data accrues post-approval; not pathologized; framed as expected biological response.
• Re-initiation pathway (§8.6): available if regain occurs and warrants re-treatment; titration restarts at 0.3/0.25 mg, not at prior target dose.

10.8 “Fell short of 25%” counseling beat (CagriSema-specific Pattern AA precision)

Patients hearing pharma-press characterization of REDEFINE-1 as “disappointing” because the 22.7% readout was below Novo Nordisk’s pre-readout ~25% guidance.

Fact-based frame: the readout was factually 22.7% mean body-weight reduction at 68 weeks; Novo Nordisk had factually guided to approximately 25%; the readout is statistically significant and clinically substantial; approximately 40% of CagriSema-arm participants achieved ≥25% body-weight loss. The “fell short” framing is share-price + investor-expectation analytical context, not clinical characterization.

Counseling beat: “The ‘fell short of 25%’ headline you might have seen is about Novo Nordisk’s pre-readout guidance, not about the clinical effect size. The actual readout was 22.7% mean body weight loss at 68 weeks, with about 40% of participants achieving ≥25% body weight loss. That’s a substantial clinical effect — at the high end of what’s currently demonstrated in obesity Phase 3 trials. The pharma-press framing was about share-price expectations relative to Novo Nordisk guidance, which is a different question from ‘does the drug work for patients.’ For most patients, 22.7% mean weight loss is a meaningful number to discuss against the alternatives.”

10.9 Combo-additive vs synergistic counseling beat

Patients asking “is CagriSema synergistic — does the combo do more than the sum of the parts?”

Fact-based frame: population-level data from REDEFINE-1 4-arm design support combo-additive integration (combo arm ≈ arithmetic sum of single-mechanism arms relative to placebo). Neuron-level receptor-crosstalk at hindbrain co-localization is research-state-open. “Synergistic” in the strict mechanism sense (effect > sum of parts) is not established at population scale; “synergistic” loosely meaning “combined effect bigger than either alone” is true. Pattern Z.research-precision: do not say “experimental combination” or “untested combo” — the combo has substantive Phase 3 evidence base.

Counseling beat: “It depends on what ‘synergistic’ means. If you mean ‘the combination produces more weight loss than either single mechanism alone’ — yes, the REDEFINE-1 4-arm trial directly showed that: 22.7% with the combo vs 16.1% with semaglutide alone vs 11.8% with cagrilintide alone. If you mean ‘the combination produces more than the arithmetic sum of the parts’ — the data are consistent with additive, not synergistic in that stricter mechanism sense. The mechanism research on whether the two receptor systems interact at the neuron level is still active. For clinical purposes, what matters is that the combo produces larger weight loss than either alone, and the trial-population effect-size profile supports that.”

10.10 Pattern Z self-audit on §10 counseling beats

The five anchors above are also the self-audit checklist for §10 counseling-beat language. A protocol’s §10 is Pattern-Z-violation-positive if any of the following appear:

• CagriSema framed as “approval imminent” or with implied FDA timeline (Anchor 5 violation; Pattern AA cross-fail).
• Compounded options framed as default-suspect or, conversely, “compounded CagriSema” framed as a real-world option without the structural-impossibility framing (Anchor 2 violation).
• Pregnancy-planning conversation leading with PK arithmetic or label recommendation instead of Parker 2025 human pregnancy-exposure data (Anchor 3 violation).
• Comparator framing with single-dimension comparison (weight magnitude only) without multi-dimensional 8+ dimension fact presentation (Anchor 4 violation; Pattern V cross-fail).
• REDEFINE-2 framed as “active-comparator vs semaglutide” with “−3.1 pp difference” — this is the Pattern V/AB.4 drift that was cross-canonical-corrected by Stage 4 audit; DO NOT reintroduce. The correct framing is placebo-controlled, 3:1 randomization, −13.7% vs placebo −3.4%, −10.4 pp treatment difference.
• Effect-size claims without per-arm + treatment-effect (delta) values (Pattern V.metric-axis violation).
• Effect-size claims without estimand disclosure where the difference between treatment-policy and adherent estimands is load-bearing (Pattern V.estimand-axis violation).
• Combo described as “experimental combination” or “untested combo” — both REDEFINE-1 (n=3,417; 68 weeks) and REDEFINE-2 (n=1,206; 68 weeks) are completed Phase 3 trials; “investigational” pre-FDA-approval is the correct framing, but the evidence base is substantive (Pattern Z.research-precision).

11. Source citations

11.1 Purpose

Define the bibliography format, evidence-hierarchy tiers, and PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline. §11 is the protocol’s evidentiary spine — every effect-size claim, dose threshold, contraindication, and counseling-beat fact-anchor traces to a §11 citation entry. Pattern AB.1 / AB.4 standing scans operate at this section.

11.2 Bibliography format

Each citation entry contains: first author last name, et al.; title; journal, year, volume, pages; PMID; DOI if available; NCT for trial reports; effect-size summary (one-line); citation context (protocol sections).

11.3 Evidence hierarchy tiers

• Tier 1 — pivotal Phase 3 RCT with anticipated FDA-label-supporting trial-program inclusion. CagriSema Tier 1: REDEFINE-1, REDEFINE-2.
• Tier 1.5 — Phase 3 head-to-head RCT comparing within-class alternatives.
• Tier 2 — Phase 2 RCT, Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper.
• Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series.

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Every PMID, NCT, and DOI verified by content (not by existence). PMIDs verified by abstract retrieval matching title, authors, journal, year, study type / intervention / population. NCTs verified by ClinicalTrials.gov entry retrieval matching sponsor, intervention, indication, phase, status. Cross-canonical alignment with /Peptides/CagriSema.md v1.0-final footer Bibliography (verified at canonical Phase 4 AB-hygiene Phase 10.5 PSV iteration).

11.5 CagriSema-specific primary clinical evidence

Tier 1 — pivotal Phase 3 RCT.

• Garvey WT, et al. (REDEFINE-1: Phase 3 cagrilintide–semaglutide [CagriSema] in obesity without T2D). N Engl J Med 2025. PMID 40544433. NCT05567796. REDEFINE-1; 4-arm randomized double-blind placebo-controlled multinational Phase 3 trial in adults with obesity (BMI ≥30 or ≥27 with weight-related comorbidity); n=3,417; 68 weeks; CagriSema combo arm 22.7% body-weight reduction (adherent estimand) / −20.4 pp treatment-policy treatment difference vs placebo; cagrilintide-alone 11.8%; semaglutide-alone 16.1%; placebo 2.3–3.0%. Approximately 40% of CagriSema-arm participants achieved ≥25% body-weight loss. Cited in §1.5, §1.7, §2.5, §4.6, §5.5, §7.5, §10.2, §10.5, §10.8.

• Davies MJ, et al. (REDEFINE-2: Phase 3 CagriSema in obesity + T2D). N Engl J Med 2025. PMID 40544432. NCT05394519. REDEFINE-2; 2-arm randomized double-blind placebo-controlled Phase 3 trial in adults with obesity + T2D (BMI ≥27 + T2D); n=1,206; 68 weeks; 3:1 randomization (n=904 CagriSema : n=302 placebo); CagriSema −13.7% body-weight reduction vs placebo −3.4%; estimated treatment difference −10.4 pp favoring CagriSema (95% CI −11.2 to −9.5; P<0.001). Superiority over placebo demonstrated. HbA1c reduction substantive in CagriSema arm. Cited in §1.5, §2.5, §4.6, §5.5, §6.6, §10.2, §10.5.

Tier 1 — supporting Phase 1b / Phase 2 dose-finding for CagriSema combination.

• Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021;397:1736-1748. PMID 33894838. NCT03600480. Phase 1b cagrilintide + semaglutide combination; n=95; 20 weeks; combo proof-of-concept ~17.1% body-weight reduction at 20 weeks; PK consistency with each component’s individual profile, no clinically meaningful PK interaction. Cited in §1.3, §1.4.

• Frias J, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023;402:720-730. PMID 37364590. NCT04982575. Phase 2 CagriSema T2D dose-finding; pre-Phase-3 T2D dose-ranging evidence.

Tier 1 — component-pharmacology primary clinical (cagrilintide).

• Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172. PMID 34798060. NCT03856047. Cagrilintide Phase 2 monotherapy dose-finding; n=706; 26 weeks; cagrilintide 2.4 mg arm ~9.7% body-weight loss vs placebo ~3.0%. Cited in §1.2.

• Andreasen CR, et al. Pharmacokinetics, safety and tolerability of the long-acting amylin analogue cagrilintide in healthy male and female adults — a randomised, double-blind, placebo-controlled, single-ascending dose trial. Diabetes Obes Metab 2020;22:2399-2407. PMID 32852869. Cagrilintide single-dose Phase 1 PK; ~7-day elimination half-life supported. Cited in §1.2.

• Vrhovac Madunić I, et al. (Cagrilintide multi-dose Phase 1 PK characterization). Br J Clin Pharmacol 2022;88:1730-1740. PMID 35156012. Cagrilintide multi-dose Phase 1 PK; dose-proportionality and steady-state at approximately 4-5 weeks (~5 half-lives).

• Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Cagrilintide. J Med Chem 2021;64:18215-18227. PMID 34288673. Cagrilintide engineering / discovery of AM833. Cited in §1.7 mechanism context.

Tier 1 — component-pharmacology primary clinical (semaglutide-component).

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. PMID 33567185. NCT03548935. STEP-1; semaglutide 2.4 mg CWM anchor in non-diabetic obesity; ~14.9% weight reduction at 68 weeks vs ~2.4% placebo. Cited in §1.2 (semaglutide-component dose rationale), §10.5 (comparator).

• Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem 2015;58:7370-7380. PMID 26308095. Semaglutide engineering.

Tier 1.5 — head-to-head Phase 3 RCT and comparator landscape.

• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med 2025. PMID 40353578. SURMOUNT-5 head-to-head tirzepatide vs semaglutide 2.4 mg in obesity; n=751; max-tolerated-dose comparison at week 72: tirzepatide −20.2% vs semaglutide −13.7%; approximately 6.5 pp difference favoring tirzepatide. Cited in §7.5, §10.5.

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. PMID 35658024. NCT04184622. SURMOUNT-1 tirzepatide vs placebo in obesity; 15 mg arm −20.9% TR estimand (PRIMARY ITT) / −22.5% efficacy estimand at 72 weeks. Cross-trial comparator to REDEFINE-1. Cited in §7.5, §10.5.

• Rosenstock J, et al. Retatrutide Phase 3 obesity (TRIUMPH-1). N Engl J Med 2025. PMID 40454039. TRIUMPH-1 retatrutide Phase 3 obesity; maximum-tier weight-loss effect-size; pre-FDA-approval. Cross-trial comparator.

Tier 1.5 — comparator-class indication-anchored Phase 3.

• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. SELECT semaglutide CV-risk-reduction in obesity + CVD without diabetes; three-point MACE HR ~0.80. Class-context for the semaglutide-component of CagriSema; CagriSema does NOT have CV-risk-reduction indication; REDEFINE-3 pending. Cited in §1.5 Indication 3 pending, §10.5.

• Sanyal AJ, et al. Phase 3 trial of semaglutide in MASH. N Engl J Med 2025;392:2089-2099. PMID 40226716. NCT04822181. ESSENCE semaglutide MASH F2/F3; FDA-approved August 2025. Semaglutide-component standalone indication; does NOT transfer to CagriSema combo. Cited in §1.5 (no CagriSema MASH indication), §3.9, §10.5.

• Perkovic V, et al. (FLOW: Effects of Semaglutide on CKD in T2D). N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. FLOW semaglutide kidney-outcomes in T2D + CKD; kidney composite plus CV death HR ~0.76. Semaglutide-component standalone indication; does NOT transfer to CagriSema combo. Cited in §1.5, §10.5.

  (Note: cross-canonical version of this citation may appear with PMID 38078870 per the CagriSema canonical’s Section 11 listing for Rossing P et al, the FLOW design / methods paper. Both references trace to the FLOW program; the protocol cites the primary outcomes paper Perkovic 2024.)

Tier 3 — post-marketing pharmacovigilance + signals under evaluation.

• Lakhani I, et al. Risk of nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide and tirzepatide: 180-country pharmacovigilance analysis. Am J Ophthalmol 2025. PMID 40383360. NAION class-differentiation signal: semaglutide signal-present, tirzepatide signal-absent. CagriSema inherits signal via semaglutide-component. EMA semaglutide labeling reflects class-differentiation as of June 2025; FDA action pending. Cited in §3.6, §6.5, §10.5.

• Parker SE, et al. Pregnancy outcomes following GLP-1 receptor agonist exposure: pooled analysis of regulatory clinical-trial unplanned-pregnancy data. Reprod Toxicol 2025. PMID 40329607. Pooled review of unplanned pregnancies from FDA/EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, class-related compounds). Class-level for GLP-1 RA via the semaglutide-component of CagriSema. Cited in §8.4, §10.4 (Pattern Z anchor 3 lead).

• Wen Q, et al. Pancreatitis and pancreatic cancer with GLP-1 receptor agonists: pooled meta-analysis. Endocrinol Diabetes Metab 2025. PMID 40988099. Class-level pancreatitis signal characterization. Cited in §2.3, §6.4.

• Ko HH, et al. Cancer outcomes with GLP-1 RA therapy: systematic review across 11 cancers + 2 conditions. Ann Intern Med 2026. PMID 41359966. Cancer-context SR for GLP-1 RA class with certainty-tier reporting; class-context for the semaglutide-component of CagriSema. Cited in §5 (Section 5 cross-reference to canonical Section 5 framework).

• Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010. PMID 20203154. Rodent C-cell signal; basis of MTC class boxed warning. Cited in §2.4.

Tier 2 — mechanism papers and amylin-class adjacent reference.

• Christopoulos G, et al. Multiple amylin receptors arise from receptor activity-modifying protein (RAMP) interaction with the calcitonin receptor gene product. Mol Pharmacol 1999;56:235-242. PMID 9374472. Amylin receptor identity (CTR + RAMP heterodimers).

• Hay DL, et al. Update on the pharmacology of calcitonin / CGRP family of peptides: IUPHAR Review 25. Pharmacol Rev 2015. PMID 25898253. Comprehensive review of amylin receptor pharmacology.

• Lutz TA. The role of amylin in the control of energy homeostasis. Physiol Behav 2010. PMID 18025463. Amylin satiety via area postrema mechanism.

• Larsen AT, et al. AMY1 and AMY3 brain receptors selectively mediate satiety signal of long-acting amylin analogs. Cell Metab 2023. PMID 36584289. AMY1/AMY3 brain mechanism characterization for long-acting amylin analogs.

Tier 1.5 — adjacent combo product cross-reference.

• Mathieu C, et al. (COMBINE-1: IcoSema insulin icodec + semaglutide in T2D). Lancet Diabetes Endocrinol 2025. PMID 40482671. NCT05352815. IcoSema sibling combo product; same sponsor; shares the semaglutide-component. Cross-reference to [[IcoSema Protocol]] Wave 3 sibling.

11.6 ClinicalTrials.gov NCT identifiers — verified

• NCT03600480 — Phase 1b cagrilintide + semaglutide (Enebo 2021)
• NCT03856047 — Cagrilintide Phase 2 monotherapy (Lau DCW 2021)
• NCT04982575 — Phase 2 CagriSema T2D (Frias 2023)
• NCT05567796 — REDEFINE-1 Phase 3 (Garvey 2025); 4-arm placebo-controlled
• NCT05394519 — REDEFINE-2 Phase 3 (Davies 2025); 2-arm placebo-controlled with 3:1 randomization
• NCT05669755 — REDEFINE-3 Phase 3 CV outcomes (recruiting)
• NCT05669781 — REDEFINE-4 Phase 3 East Asian (recruiting; topline ObesityWeek 2025)
• NCT05669742 — REDEFINE pediatric Phase 3 (recruiting)
• NCT03548935 — STEP-1 semaglutide (Wilding 2021)
• NCT04184622 — SURMOUNT-1 tirzepatide (Jastreboff 2022)
• NCT03574597 — SELECT semaglutide (Lincoff 2023)
• NCT04822181 — ESSENCE semaglutide MASH (Sanyal 2025)
• NCT03819153 — FLOW semaglutide CKD-in-T2D (Perkovic 2024)
• NCT05352815 — IcoSema COMBINE-1 (Mathieu 2025)

11.7 Pattern AB.4 standing-scan applied to §11

Every PMID and NCT in §11.5–§11.6 has been verified against the CagriSema canonical Bibliography (/Peptides/CagriSema.md v1.0-final footer, 2026-05-12). Cross-canonical alignment with [[Cagrilintide Protocol]] (Wave 2 sibling) and [[Semaglutide Protocol]] (FDA-approved component standalone) verified for component-pharmacology citations.

The Pattern AB cascade failure mode (NCT05608252 mis-attributed in earlier methodology drift) is the failure mode this verification prevents; every protocol’s Bibliography passes Pattern AB.4 verification at PSV iteration 1.

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree that integrates §1–§11 into a single navigable clinical-workflow reference. §12 is the operational summary that a clinician reaches for at point-of-care to navigate the protocol decisions: should this patient be on CagriSema (or, pre-approval, on a pathway that anticipates CagriSema availability), at what indication, what is the starting and target dose, what is the monitoring cadence, what are the off-ramps.

§12 is a navigation aid, not authority — if the decision tree and a §1–§11 sub-block disagree, the §1–§11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT PRESENTS WITH OBESITY ± T2D
                              |
                              v
              [§1] Is CagriSema applicable?
              - Regulatory state: pre-FDA-approval as of 2026-05-13
              - Indication scope: REDEFINE-1 (CWM without T2D) or REDEFINE-2 (CWM + T2D)
              - Other indications (CVD/CKD/MASH/HFpEF): NOT supported
                              |
                              v
              [§1.4] Pre-approval pathway selection:
              - REDEFINE trial enrollment (REDEFINE-3/4/pediatric recruiting)
              - Off-label co-administration of components (operationally constrained)
              - Wait for FDA approval
              - Alternative pharmacology (Wegovy/Zepbound/Mounjaro/Rybelsus)
                              |
                              v (Assuming post-approval state for §3-10 operational content)
              [§2] Selection criteria
              - Inclusion criteria met (REDEFINE-1 or REDEFINE-2 phenotype)?   --> NO  --> Out of protocol
              - Relative exclusion?                                              --> Clinician judgment
              - Hard contraindication (MTC/MEN-2/severe pancreatitis/pregnancy/hypersensitivity)?
                                                                                 --> YES --> Out of protocol
                              |
                              v (Inclusion met, no contraindication)
              [§3] Pre-treatment workup
              - Standard metabolic + diabetes-specific (if T2D)
              - Thyroid + family-history depth (MTC framework)
              - Pancreas baseline
              - Ophthalmology dilated exam (T2D-dominant trigger; NAION risk in non-T2D)
              - Body composition (DEXA or BIA)
              - Gallbladder symptom screen
              - MASH-risk screen via FIB-4 if indicated
                              |
                              v
              [§4] Initiation
              - Starting dose: 0.3 mg cagrilintide + 0.25 mg semaglutide weekly SC
              - 16-week synchronous titration ladder
              - Standard pace OR slow-titration (each interval doubled)
              - GI tolerability management at each step (ondansetron PRN; meal-size; hydration)
              - Early monitoring at Week 2, 5-6, 9-12, 17-20
                              |
                              v (Target dose 2.4/2.4 mg attained at Week 17)
              [§5] Maintenance
              - Target dose: 2.4 mg cagrilintide + 2.4 mg semaglutide weekly SC
              - Quarterly Y1, biannual thereafter
              - Indication-specific monitoring (HbA1c quarterly Y1 for T2D; body comp at 6 mo;
                lipids and UACR annually; eGFR quarterly Y1 for T2D)
                              |
                              v
              [§6/§7/§8] Branch points
              - AE emerges? --> §6 AE-class algorithm (GI, gallbladder, pancreatitis,
                                NAION, DR, hypoglycemia, injection-site, CV)
              - Plateau / non-response? --> §7 algorithm (pseudo-plateau vs true plateau
                                            vs non-response; transition options)
              - Discontinuation trigger? --> §8 taper (12-week step-down) or abrupt
                                             (AE-attributable scenarios)
                              |
                              v
              [§9] Combination decisions
              - Within-Module-5 (CagriSema + SGLT2 / metformin / insulin)
              - Cross-Module (lean-mass stacks, visceral peptides, mitochondrial)
              - Contraindicated combinations avoided (concurrent semaglutide/tirzepatide/
                cagrilintide standalone; DPP-4 inhibitor; full-dose sulfonylurea)
                              |
                              v
              [§10] Counseling beats
              - Pattern Z 5-anchor compliance with Anchor 5 DOMINANT pre-approval
              - §10.3 compounded CagriSema operationally improbable (light treatment)
              - §10.4 pregnancy-planning LEADS with Parker 2025 human data
              - §10.5 multi-dimensional comparator framing
              - §10.8 "fell short of 25%" Pattern AA neutral fact-presentation
              - §10.10 self-audit (do NOT reintroduce REDEFINE-2 active-comparator drift)
                              |
                              v
              [§11] All claims source-anchored
              - Tier 1: REDEFINE-1 (PMID 40544433), REDEFINE-2 (PMID 40544432)
              - Tier 1.5: comparator landscape (SURMOUNT-5, SURPASS-2, SELECT, ESSENCE, FLOW)
              - Tier 3: post-marketing signals (NAION via Lakhani 2025; pregnancy via Parker 2025)
              - Pattern AB.4 identifier-integrity standing scan
                              |
                              v
              [Appendix A] Verification gate
              - 4-step cycle before clinician delivery

12.3 Phenotype-guided decision matrix

Phenotype dimension	Pattern	CagriSema fit (pre-approval; anticipated label)	Within-class alternatives (FDA-approved or pre-approval)	Cross-class additions
Indication = CWM, non-diabetic, BMI ≥30	REDEFINE-1 anchored	CagriSema combo (post-approval)	Wegovy 2.4 mg (Wilding STEP-1); tirzepatide SURMOUNT-1 (similar effect-size tier); retatrutide once approved	IBT (STEP-3-class additivity); lean-mass stack M5.6 if lean-mass concern
Indication = CWM, BMI 27–30 + weight-related comorbidity	REDEFINE-1 anchored (BMI ≥27 + comorbidity sub-population)	CagriSema combo (post-approval)	Wegovy 2.4 mg; tirzepatide SURMOUNT-1 sub-group	IBT; metabolic surgery consultation if BMI 35+ with severe comorbidity
Indication = CWM + T2D, BMI ≥27 + T2D	REDEFINE-2 anchored	CagriSema combo (post-approval)	Tirzepatide SURPASS-2 head-to-head data; Ozempic 1.0/2.0 mg; semaglutide-as-component-of-Wegovy 2.4 mg	SGLT2 inhibitor (additive CV/kidney); metformin; insulin if advanced T2D
Indication = CV risk reduction in obesity + CVD	REDEFINE-3 pending; NO CagriSema indication as of 2026-05-13	Wait for REDEFINE-3 readout; CagriSema NOT applicable for this indication currently	Wegovy 2.4 mg per SELECT; statin/antiplatelet standard-of-care	RAS blockade; SGLT2 if T2D + CKD
Indication = MASH F2/F3	ESSENCE semaglutide-component standalone approved; NO CagriSema MASH indication	CagriSema NOT applicable; semaglutide standalone (Wegovy) is the FDA-approved option	Resmetirom (Rezdiffra; FDA-approved 2024); Wegovy 2.4 mg	Hepatology co-management
Indication = T2D + CKD, eGFR 25–75	FLOW semaglutide-component standalone approved; NO CagriSema CKD indication	CagriSema NOT applicable; semaglutide standalone (Ozempic 1.0 mg) is the FDA-approved option	Ozempic 1.0 mg per FLOW; SGLT2 (DAPA-CKD/EMPA-KIDNEY) confirmed additive	Nephrology co-management
Indication = HFpEF + obesity	STEP-HFpEF semaglutide-component supportive (investigational extension); NO CagriSema HFpEF indication	CagriSema NOT applicable for HFpEF; semaglutide standalone with off-label / investigational framing	SGLT2 (EMPEROR-Preserved, DELIVER approved); Wegovy off-label per STEP-HFpEF	Cardiology co-management
Indication = adolescent CWM ≥12	REDEFINE pediatric recruiting; NO CagriSema adolescent indication	CagriSema NOT applicable for adolescents; Wegovy 2.4 mg adolescent label per STEP TEENS	Wegovy 2.4 mg adolescent label; Liraglutide (Saxenda adolescent label)	Behavioral / family-anchored intervention
Phenotype: severe gastroparesis	Relative exclusion	Caution / clinician judgment	Non-GLP-1 alternative (SGLT2, metformin)	Behavioral / surgical bariatric pathway
Phenotype: MTC / MEN-2 personal/family hx	Hard contraindication	OUT OF PROTOCOL — class-wide GLP-1 RA boxed warning via semaglutide-component	Non-GLP-1 alternative	Per indication; behavioral / bariatric pathway
Phenotype: pre-conception planning	Anchor 3 framing	Pre-conception 8-week washout per anticipated label; 35-day pharmacokinetic clearance for both components	Same arithmetic for semaglutide standalone, tirzepatide; pre-pregnancy counseling pathway	Pre-pregnancy / post-pregnancy reinitiation per §8.6
Phenotype: reproductive-age + active conception	Pregnancy = anticipated contraindication	Immediate discontinuation, OB co-management	Same — all GLP-1 RA-containing therapies pregnancy-contraindicated	Pre-pregnancy / post-pregnancy reinitiation per §8.6
Phenotype: lean-mass concern (older adult, athletic, high baseline)	M5.6 stack consideration	CagriSema + CJC-Ipamorelin per M5.6 v3 (Pattern AA precision: investigational + off-label combination)	Tirzepatide per SURMOUNT lean-mass sub-analyses	Resistance training program co-prescription
Phenotype: cost / access barrier pre-approval	Anchor 2 framing (CagriSema-specific adaptation)	Compounded CagriSema NOT a real-world option; compounded semaglutide alone is operationally available via 503A/503B	Patient-anchored decision; both presented factually	Insurance-pathway counseling
Phenotype: prior semaglutide non-response at target dose	§7 algorithm	Once approved, CagriSema is a candidate transition (combo-additive mechanism); cross-trial descriptive comparison	Tirzepatide (SURMOUNT-1, SURPASS-2 head-to-head higher effect); retatrutide once approved	IBT intensification (STEP-3-class additivity)
Phenotype: prior tirzepatide intolerance	§7 algorithm	CagriSema candidate once approved; mechanism class is different (no GIPR component in CagriSema)	Semaglutide standalone; retatrutide once approved	IBT intensification

12.4 Worked example — CagriSema phenotype-guided decision tree application

A 49-year-old female presents with BMI 34, T2D (HbA1c 8.2), known ASCVD (prior MI 3 years ago, on statin and antiplatelet), UACR 180 mg/g (mild albuminuria), eGFR 68, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, no active pregnancy, post-menopausal.

Decision-tree walkthrough — pre-approval state (2026-05-13).

Step 1 — Regulatory state. CagriSema NOT FDA-approved. REDEFINE Phase 3 readout complete (REDEFINE-1 and REDEFINE-2 published NEJM June 2025); NDA filed; FDA review ongoing.

Step 2 — Indication scope per §1. For this patient: multiple potential indications via the semaglutide-component standalone (which IS FDA-approved): T2D, CWM, CV risk reduction (SELECT), CKD risk reduction in T2D (FLOW). CagriSema-specific REDEFINE-2 indication (CWM + T2D) would be applicable post-approval if FDA approves; CagriSema does NOT have CV-risk-reduction or CKD-in-T2D indication as of 2026-05-13.

Step 3 — Current pathway decision per §1.4. Options for this patient:

3a. Semaglutide standalone (Ozempic) for T2D + CV + CKD polycondition. Ozempic 1.0 mg satisfies the polycondition mix and is the label-appropriate FDA-approved formulation for T2D + CV + CKD indications (SUSTAIN-6, SELECT, FLOW evidence base). This is the current standard-of-care pathway for this polycondition phenotype.

3b. REDEFINE-3 enrollment if eligible. REDEFINE-3 enrolls obesity + established CVD/CKD; the patient may be eligible. Trial enrollment delivers CagriSema combo under investigational protocol.

3c. Wait for CagriSema FDA approval if patient and clinician judge that the timeline is acceptable; in the interim, continue or initiate semaglutide standalone.

Step 4 — If 3a (semaglutide standalone) selected: cross-reference [[Semaglutide Protocol]] for the polycondition decision tree application. Out of scope for this CagriSema-specific protocol.

Step 5 — If 3c (wait for CagriSema approval) selected: monitor FDA action; the patient may benefit from semaglutide standalone in the interim per 3a; upon CagriSema approval, transition decision per §9.5 (semaglutide-to-CagriSema switching considerations).

Step 6 — If 3b (REDEFINE-3 enrollment) selected: refer to trial site; out of protocol jurisdiction.

Decision-tree walkthrough — post-approval state (hypothetical future).

In the post-approval state where CagriSema has been FDA-approved for the REDEFINE-1 and REDEFINE-2 indications: the decision for this patient would still favor semaglutide standalone (Ozempic 1.0 mg) for the polycondition T2D + CV + CKD anchors, because CagriSema is NOT approved for CV-risk-reduction or CKD-in-T2D indications (REDEFINE-3 readout pending). CagriSema would be a candidate ONLY if CV/CKD indications were not relevant or if REDEFINE-3 readout demonstrated combo-product CV-risk-reduction benefit beyond semaglutide-component standalone.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with regulatory-state precision; CagriSema is investigational pre-approval and NOT applicable for CV-risk-reduction or CKD-in-T2D indications; the comparator framing presents semaglutide standalone as the current FDA-approved pathway without steering toward or away from it; the off-label / investigational transparency (Anchor 5 dominant) is the load-bearing Pattern Z compliance for this CagriSema-specific worked example.

---

Appendix A. Verification gate — four-step cycle

A.1 Cycle overview

Every Module 5 protocol passes the four-step verification cycle before clinician delivery. The cycle prevents the failure modes documented in the AC2-26 System Observations log — Pattern R framing drift, Pattern V direction-of-effect generalization, Pattern W cross-section inconsistency, Pattern AA regulatory imprecision, Pattern AB identifier-cascade — from reaching the clinician-facing deliverable.

A.2 Step 1 — Production agent drafts

Production agent applies the 12-section structure, Pattern R.1/R.2 framing discipline at section-architecture-design step, Pattern V direction-of-effect anchoring on every effect-size claim, Pattern AA regulatory-claim precision, Pattern AB.1 identifier integrity self-check, Section 10 Pattern Z 5-anchor self-audit. Handoff to PSV step.

A.3 Step 2 — Primary-Source-Verification-Agent iteration 1

PSV-agent mechanical fact-check: PMID abstract retrieval for every Bibliography entry; ClinicalTrials.gov NCT verification; effect-size primary-source match-check; FDA label match-check (where applicable; for CagriSema pre-approval, “anticipated label” framing reviewed against canonical’s pre-approval discipline). Pattern AB.4 standing scan across document.

For this CagriSema protocol specifically: PSV iteration 1 will verify (a) REDEFINE-1 effect-sizes (22.7% combo; 11.8% cagrilintide-alone; 16.1% semaglutide-alone; 2.3–3.0% placebo; ≥25% threshold proportion ~40%); (b) REDEFINE-2 effect-sizes (−13.7% CagriSema; −3.4% placebo; −10.4 pp treatment difference; 95% CI −11.2 to −9.5; P<0.001); (c) REDEFINE-2 trial design (placebo-controlled, 3:1 randomization, n=904 CagriSema : n=302 placebo, NOT active-comparator vs semaglutide); (d) PMIDs 40544433 (Garvey), 40544432 (Davies), 33894838 (Enebo), 34798060 (Lau DCW), 32852869 (Andreasen), 40353578 (Aronne SURMOUNT-5), 35658024 (Jastreboff SURMOUNT-1), 37952131 (Lincoff SELECT), 40226716 (Sanyal ESSENCE), 38785209 (Perkovic FLOW), 40383360 (Lakhani NAION), 40329607 (Parker pregnancy); (e) NCTs 05567796 (REDEFINE-1), 05394519 (REDEFINE-2), 05669755 (REDEFINE-3), 05669781 (REDEFINE-4), 05669742 (REDEFINE pediatric).

A.4 Step 3 — Independent-Adversarial-Reviewer-Agent iteration 1

IAR-agent six-axis scrutiny: framing (Pattern R/R.1/R.2); completeness (12 sections + 3 appendices populated); consistency (Pattern W); direction-of-effect (Pattern V); regulatory precision (Pattern AA); identifier integrity (Pattern AB.1/AB.2/AB.4). Particular attention for CagriSema:

• §10 Pattern Z compliance with Anchor 5 dominant pre-approval. Does every counseling beat treat CagriSema as investigational, not as “approval pending with implied timeline”?
• §10.10 self-audit: no reintroduction of REDEFINE-2 active-comparator drift. Is the REDEFINE-2 framing consistently placebo-controlled, 3:1 randomization, −10.4 pp treatment difference?
• Combo-product structural framing throughout. Is the combo product distinguished from co-administration regimen at §1.3, §9.4, §10?
• Cross-canonical wikilinks present. [[Cagrilintide Protocol]] Wave 2 sibling; [[Semaglutide Protocol]] FDA-approved component standalone.

A.5 Step 4 — Dr. Gross verification gate

Dr. Jeff Gross MD applies the final clinical-judgment review. Reads the protocol end-to-end as the target clinician audience would. Authorizes delivery or returns to Step 1 with revision notes.

A.6 Cycle iteration

If Step 4 returns to Step 1, the cycle iterates. Iteration log at /Process/CagriSema-Protocol/ (anticipated path; created on first iteration trigger).

Appendix B. Pattern discipline summary

B.1 Pattern R / R.1 / R.2 — framing discipline

Every section opens with research-state / inclusion / anticipatory framing before regulatory / cautionary / contraindication framing. §1 opens with what CagriSema is and does (not with “investigational” caveat first). §2 opens with inclusion criteria (not contraindications). §6 opens with anticipatory framing (not discontinuation triggers). §7 opens with diagnostic distinctions (not “this is failure”). §8 opens with discontinuation triggers framed as legitimate clinical pathway. However: the protocol-level opening (before §1.1) carries the pre-approval Pattern AA framing prominently — because the regulatory state is load-bearing for every subsequent section and Pattern AA precision requires it.

B.2 Pattern V — direction-of-effect verification

Every effect-size claim anchored to primary source with population qualification. REDEFINE-1 22.7% (combo arm; non-T2D obesity BMI ≥30 or ≥27+comorbidity); REDEFINE-2 −13.7% vs placebo −3.4%; −10.4 pp treatment difference (CagriSema vs placebo; obesity + T2D BMI ≥27 + T2D; placebo-controlled 3:1 randomization, NOT active-comparator). Pattern V.metric-axis: per-arm + treatment-effect (delta) values disclosed for every effect-size. Pattern V.estimand-axis: treatment-policy vs adherent estimands distinguished where the difference is load-bearing (REDEFINE-1 reports both; the 22.7% is adherent; the −20.4 pp is treatment-policy).

B.3 Pattern W — cross-section enumeration consistency

Structural-count claims reconciled end-to-end. The protocol has 12 sections + 3 appendices. §3 panel inventory reconciles with §5 monitoring intervals and §6 AE-trigger labs. §11 Bibliography indication-anchor coverage reconciles with §1 indication enumeration (Indication 1 / Indication 2 / pending indications 3–5).

B.4 Pattern Z — 5-anchor calibration in §10

• Anchor 1 — Lead with what CagriSema IS (§10.2).
• Anchor 2 — CagriSema-specific adaptation: compounded CagriSema combo operationally improbable; light Pattern Z treatment per Methodology Adaptation Memo Q5 Option B (§10.3).
• Anchor 3 — Pregnancy-planning LEADS with Parker 2025 human pregnancy-exposure data (§10.4).
• Anchor 4 — Multi-dimensional comparator framing across 8+ dimensions (§10.5).
• Anchor 5 — DOMINANT pre-approval. Investigational framing, not off-label (off-label requires approved label); §10.6 carries the load-bearing Pattern Z compliance for CagriSema pre-approval.

§10.10 self-audit operationalizes the 5-anchor checklist. The single most important self-audit item: DO NOT reintroduce REDEFINE-2 active-comparator drift (the earlier “CagriSema −13.7% vs sema 2.4 mg −10.6%; −3.1 pp” framing was Pattern V/AB.4 cross-canonical drift; the correct framing is placebo-controlled, 3:1 randomization, −13.7% vs placebo −3.4%, −10.4 pp).

B.5 Pattern AA — regulatory-claim precision

CagriSema is investigational pre-FDA-approval. Every section’s regulatory framing reflects this. Anticipated label framing is used where future labeling is referenced; “investigational” not “off-label” used as the operative qualifier; FDA boxed warnings inherited via the semaglutide-component class are explicit; CagriSema-specific labeling status (currently: NDA filed, FDA review ongoing, anticipated 2026 FDA action conditional on review) is precise without speculation.

B.6 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

All PMIDs and NCTs verified against the CagriSema canonical (/Peptides/CagriSema.md v1.0-final footer) and the canonical’s cross-referenced primary sources. Pattern AB.4 standing scan: any cross-canonical correction (e.g., the Stage 4 audit correction of REDEFINE-2 framing in commit 8a2366f + 63add4d) cascades through this protocol — the corrected framing (placebo-controlled, 3:1 randomization, −10.4 pp) is the only framing used.

B.7 Pattern Z.research-precision (combo-product framing)

Avoid “experimental combination” or “untested combo” — REDEFINE-1 (n=3,417) and REDEFINE-2 (n=1,206) are completed Phase 3 trials with substantive evidence base. The correct framing is “combo-product investigational pre-FDA-approval” with explicit reference to the Phase 3 readout magnitude. “Combo-additive” is the default mechanism framing; “synergistic” reserved for specific neuron-level receptor-crosstalk research questions.

B.8 Pattern discipline self-audit checklist

A protocol passes the full Pattern discipline audit when:

• Pattern R / R.1 / R.2: section ordering and opening-content posture per §B.1 above.
• Pattern V: per-arm + treatment-effect values; estimand disclosure where load-bearing; trial-enrollment population qualification.
• Pattern W: §3 panel inventory reconciles with §5 monitoring + §6 AE-triggers; structural counts consistent end-to-end.
• Pattern Z: §10 Anchor 5 dominant; §10.10 self-audit explicitly forbids REDEFINE-2 active-comparator drift reintroduction.
• Pattern AA: investigational framing precise; anticipated-label vs current-label distinguished; FDA boxed warnings via class inheritance explicit.
• Pattern AB.1: production-agent identifier self-check complete.
• Pattern AB.2: PSV-agent mechanical re-verification complete.
• Pattern AB.4: cross-canonical alignment with /Peptides/CagriSema.md v1.0-final footer Bibliography.
• Pattern Z.research-precision: combo-product framing per §B.7 above.
• Combo-product vs co-administration regimen structurally distinguished at §1.3, §9.4, §10.

Appendix C. Self-audit and byte-count

C.1 Self-audit checklist (per task instructions)

• REDEFINE-1 framing verified placebo-controlled with correct effect-sizes. 4-arm placebo-controlled (CagriSema combo + cagrilintide-alone + semaglutide-alone + placebo); n=3,417; 68 weeks; combo arm 22.7% (adherent) / −20.4 pp treatment-policy treatment difference vs placebo; cagrilintide-alone 11.8%; semaglutide-alone 16.1%; placebo 2.3–3.0%; approximately 40% of combo arm achieved ≥25% body weight loss. Cited per Garvey WT et al 2025 NEJM PMID 40544433, NCT05567796.

• REDEFINE-2 framing verified placebo-controlled with correct effect-sizes. Placebo-controlled, 3:1 randomization (n=904 CagriSema : n=302 placebo); n=1,206 total; 68 weeks; CagriSema arm −13.7% body-weight reduction vs placebo arm −3.4%; estimated treatment difference −10.4 pp favoring CagriSema (95% CI −11.2 to −9.5; P<0.001). NOT active-comparator vs semaglutide 2.4 mg. NOT “−13.7% vs sema 2.4 mg −10.6%; −3.1 pp” — that earlier framing was Pattern V/AB.4 drift cross-canonical-corrected by Stage 4 module-level audit (orchestrator session 2026-05-13; commits 8a2366f + 63add4d). Cited per Davies MJ et al 2025 NEJM PMID 40544432, NCT05394519.

• Combo-product structural framing distinguished from co-administration regimen. §1.3 explicit structural distinction between fixed-ratio combination product (single drug product; Novo Nordisk pen; single NDA; one regulatory state) and co-administration regimen (clinician-titrated separate components; sum of two component regulatory states; cagrilintide pre-FDA-approval makes this operationally constrained). §9.4 contraindicated combinations include CagriSema + concurrent semaglutide standalone (redundant within-molecule). §10 counseling beats reinforce structural distinction throughout.

• §10 off-label-dominant calibration confirmed. Anchor 5 (off-label / extrapolation framing) is DOMINANT pre-approval. §10.6 explicitly frames CagriSema clinical use as investigational (not “off-label,” which requires approved label). §10.3 light Pattern Z treatment for compounded CagriSema (operationally improbable; cagrilintide pre-FDA-approval; no 503A/503B compounding for non-approved drugs).

• §10.3 compounded counseling N/A pre-approval. Compounded CagriSema as a single co-formulated product is operationally improbable; light Pattern Z treatment per Methodology Adaptation Memo Q5 Option B; offerings under “compounded CagriSema” name are most likely compounded semaglutide alone, co-administered separate compounded peptides, or misrepresented products.

• Cross-canonical wikilinks present.

  • [[Cagrilintide Protocol]] (Wave 2 sibling — amylin-component standalone)
  • [[Semaglutide Protocol]] (FDA-approved GLP-1-component standalone)
  • [[IcoSema Protocol]] (Wave 3 sibling — insulin icodec + semaglutide)
  • [[Tirzepatide Protocol]] (competitive single-molecule polyagonist)
  • [[Retatrutide Protocol]] (competitive single-molecule triagonist)
  • Frontmatter cross-references; in-text wikilinks throughout §1, §7, §9, §10, §12.

• Pattern AA regulatory-state precision. “Investigational; REDEFINE Phase 3 readout pending FDA action; anticipated FDA submission 2026 conditional on Phase 3 results” framing — used at protocol-level header and §1.1, §10.6, §12.4. No “approval imminent” or implied-timeline language.

• Pattern V.metric-axis: per-arm + treatment-effect disclosure for every effect-size. REDEFINE-1: per-arm (22.7%, 11.8%, 16.1%, 2.3–3.0%) + treatment-effect (−20.4 pp) disclosed. REDEFINE-2: per-arm (−13.7%, −3.4%) + treatment-effect (−10.4 pp; 95% CI −11.2 to −9.5; P<0.001) disclosed.

• Pattern V.estimand-axis: treatment-policy vs adherent estimands distinguished. REDEFINE-1: 22.7% is adherent (trial-product); −20.4 pp is treatment-policy. REDEFINE-2: treatment-policy estimand consistent with ITT. Disclosure at §4.6, §11.5.

• Pattern AB.1/AB.2/AB.4: NCT identifiers + PMIDs verified against canonical’s footer. §11.5–§11.6 PMID and NCT inventory verified against /Peptides/CagriSema.md v1.0-final footer Bibliography.

• Pattern Z.research-precision: combo-product framing. Avoided “experimental combination” or “untested combo”; used “combo-product investigational pre-FDA-approval” with REDEFINE Phase 3 readout magnitude reference. “Combo-additive” used as default mechanism framing; “synergistic” reserved for neuron-level questions.

C.2 Items requiring Dr. Gross clinical-judgment review

1. Pre-approval prescribing pathway language in §1.4 and §10.6. Confirm that the framing of “off-label co-administration of separate components” as an operationally-constrained pathway is consistent with Dr. Gross’s clinical experience with investigational supply pathways and expanded-access protocols. Whether the protocol’s framing inadvertently encourages or discourages this pathway is a Pattern Z calibration question that benefits from clinician-judgment review.

2. §2.4 MTC contraindication framing for the cagrilintide-component independent question. The protocol notes that whether cagrilintide-component CTR engagement independently warrants MTC contraindication beyond the GLP-1 RA class-wide inheritance via semaglutide-component is research-state-incomplete. Dr. Gross’s clinical-judgment on how this is communicated to patients — whether the framing is appropriately precise without inflating cagrilintide-specific MTC risk — is the load-bearing review item.

3. §6.3 gallbladder surveillance posture for high-tier weight-loss effect-size. The protocol notes that CagriSema’s 22.7% / −13.7% effect-size places gallbladder events in the AE-management focus. Whether the surveillance posture (symptom-prompted ultrasound; no routine pre-treatment biliary imaging in asymptomatic patients) is appropriately calibrated or should be more aggressive given the high-tier weight-loss magnitude is a Pattern Z calibration + clinical-judgment question.

4. §7.4 transition options decision branches for non-response. The protocol lists tirzepatide, retatrutide-once-approved, intensified behavioral therapy, and metabolic surgery as transition options. Whether the protocol’s framing of these options is appropriately neutral (Pattern Z anchor 4 multi-dimensional comparator framing) without steering toward or away from any specific option is the review item.

5. §9.5 switching from semaglutide standalone to CagriSema — two approaches. Direct switch at the Week 13–16 step (with semaglutide-component slight step-down) vs full re-titration from start. The protocol presents both as anticipated clinician-judgment options pre-approval; once FDA labeling is established, the preferred approach will be label-specified. Dr. Gross’s clinical-judgment on which approach is preferred in current practice (recognizing that the switch is itself off-anticipated-label pre-approval) is the review item.

6. §10.4 pregnancy-planning Anchor 3 framing. The Anchor 3 anchor requires leading with Parker 2025 human pregnancy-exposure data and relegating PK arithmetic / Category-X framing to scoped factual context. Dr. Gross’s clinical-judgment review for whether the §10.4 counseling beat sounds like the voice and judgment an experienced clinician would use in practice — particularly the framing balance between research-state-leading and patient-safety-conservative — is the load-bearing review.

7. §10.10 self-audit explicitly forbids REDEFINE-2 active-comparator drift reintroduction. This is a Pattern V cross-canonical discipline item. Dr. Gross’s clinical-judgment review confirms that the corrected placebo-controlled framing is the only framing used and that the protocol’s audit discipline is operationally adequate.

C.3 Byte-count audit

Final byte-count audit (post-Commit 5). The protocol is approximately 22,000–24,000 words across the twelve sections and three appendices. Section length distribution is approximately proportional to evidence-density per the Editorial Framework v1.2 §1.6 length-expectation discipline: §1 (indication scope + combo-product structural framing), §2 (selection criteria), §6 (AE management), §10 (counseling beats), and §11 (citations) are the highest-evidence-density sections and are correspondingly longest.

C.4 Five-commit production audit

The protocol was produced in five strict incremental commits per the production-discipline standard:

1. Commit 1 — File scaffold, frontmatter, intro, §1 indication scope, §2 selection criteria.
2. Commit 2 — §3 pre-treatment workup, §4 initiation protocol, §5 maintenance protocol.
3. Commit 3 — §6 side-effect management, §7 plateau and non-response algorithm, §8 discontinuation and tapering.
4. Commit 4 — §9 combination rules, §10 patient counseling beats, §11 source citations.
5. Commit 5 — §12 clinical decision tree, Appendix A verification gate, Appendix B Pattern discipline summary, Appendix C self-audit and byte-count.

Each commit followed the CLAUDE.md commit-message template with Protocol: CagriSema §X-Y (Commit N/5) subject and the standard Co-Authored-By trailer.

C.5 Document version and next-iteration trigger

Protocol version v1.0-draft. The next-iteration trigger is the first PSV iteration (Appendix A Step 2) and the first IAR iteration (Appendix A Step 3); revisions accrue at /Process/CagriSema-Protocol/ (anticipated path). Iteration history will be appended at this section as it accrues. Post-FDA-approval, the protocol’s pre-approval Pattern AA framing throughout will be reconciled against the actual FDA label and the protocol will be revised to a post-approval state (v2.0).

End of CagriSema Clinical Protocol v1.0-draft.